+关注
SherryVJ
seraph & smiles!
IP属地:未知
386
关注
104
粉丝
0
主题
0
勋章
主贴
热门
SherryVJ
2021-12-18
Tiger
EV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7% and General Motors sliding 5%
SherryVJ
2021-12-15
[Shy] [Shy] [Shy] [Shy]
U.S. retail sales climb tepid 0.3% in November as Americans confront high inflation
SherryVJ
2021-12-13
Oh my con
Arena Pharmaceuticals jumped over 80% in morning trading as Pfizer acquired it for US $100/share
SherryVJ
2021-12-11
Ok
Hedge Funds Ensnared in Expansive DOJ Probe Into Short Selling
SherryVJ
2021-12-11
✅
US STOCKS-Wall Street gains, S&P hits record closing high as CPI meets expectations
SherryVJ
2021-12-10
Oh
Some vaccine stocks dropped in premarket trading
SherryVJ
2021-12-10
Down
抱歉,原内容已删除
SherryVJ
2021-12-09
Go
Amazon shares fell slightly by 0.5% in premarket trading
SherryVJ
2021-12-08
Woo
抱歉,原内容已删除
SherryVJ
2021-12-07
999
777 Partners Orders 30 Additional 737 MAX Airplanes
SherryVJ
2021-12-07
Oh
3 Dow Stocks Begging to Be Bought in December
SherryVJ
2021-12-07
$Twitter(TWTR)$
เธอสั่งให้รอฉันก็รออย่างมีจุดหมาย
SherryVJ
2021-12-07
👍
RIVN Price Prediction: Why One Analyst Sees Rivian Stock Hitting $147
SherryVJ
2021-12-06
Downstairs
Why American Eagle Outfitters Is Jumping 5.5% Today
SherryVJ
2021-12-04
😢
Hot chinese concept stocks dipped in morning trading
SherryVJ
2021-12-03
Good
Moderna stock jumped more than 5% in premarket trading
SherryVJ
2021-12-02
Ok
Glaxo says its vaccine retains activity against key Omicron mutations
SherryVJ
2021-12-02
$NIO Inc.(NIO)$
Wow nice
SherryVJ
2021-12-02
$Twitter(TWTR)$
Bit by bit
SherryVJ
2021-12-02
Thanks
Singapore Stocks to watch: SPH, SPH Reit, Keppel, Sembcorp, Ntegrator
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3586426326873853,"uuid":"3586426326873853","gmtCreate":1623381375220,"gmtModify":1628402107333,"name":"SherryVJ","pinyin":"sherryvj","introduction":"","introductionEn":"","signature":"seraph & smiles!","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":104,"headSize":386,"tweetSize":373,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.01%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.58%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":699146410,"gmtCreate":1639759405628,"gmtModify":1639760513920,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Tiger","listText":"Tiger","text":"Tiger","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/699146410","repostId":"1113440959","repostType":4,"repost":{"id":"1113440959","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639752802,"share":"https://www.laohu8.com/m/news/1113440959?lang=&edition=full","pubTime":"2021-12-17 22:53","market":"us","language":"en","title":"EV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7% and General Motors sliding 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113440959","media":"Tiger Newspress","summary":"EV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7%, Lordstown","content":"<p>EV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7%, Lordstown Motors sliding 6% and General Motors sliding 5%.<img src=\"https://static.tigerbbs.com/cd629a366b9a963976bc2a56e7c34763\" tg-width=\"282\" tg-height=\"468\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7% and General Motors sliding 5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7% and General Motors sliding 5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-17 22:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>EV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7%, Lordstown Motors sliding 6% and General Motors sliding 5%.<img src=\"https://static.tigerbbs.com/cd629a366b9a963976bc2a56e7c34763\" tg-width=\"282\" tg-height=\"468\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LCID":"Lucid Group Inc","GM":"通用汽车","RIVN":"Rivian Automotive, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113440959","content_text":"EV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7%, Lordstown Motors sliding 6% and General Motors sliding 5%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":652,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607438496,"gmtCreate":1639576827511,"gmtModify":1639576828652,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[Shy] [Shy] [Shy] [Shy] ","listText":"[Shy] [Shy] [Shy] [Shy] ","text":"[Shy] [Shy] [Shy] [Shy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/607438496","repostId":"1148643584","repostType":4,"repost":{"id":"1148643584","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639575903,"share":"https://www.laohu8.com/m/news/1148643584?lang=&edition=full","pubTime":"2021-12-15 21:45","market":"us","language":"en","title":"U.S. retail sales climb tepid 0.3% in November as Americans confront high inflation ","url":"https://stock-news.laohu8.com/highlight/detail?id=1148643584","media":"Tiger Newspress","summary":"The numbers: Amazon, Target and other retailers posted a small 0.3% increase in sales in November at","content":"<p><b>The numbers:</b> Amazon, Target and other retailers posted a small 0.3% increase in sales in November at the start of the holiday season, but if high inflation is taken into account, receipts fell in a weak showing for the economy.</p>\n<p></p>\n<p>Economists polled by The Wall Street Journal had forecast a 0.8% increase.</p>\n<p>The increase in sales was outstripped by a rising cost of living. The consumer price index jumped 0.8% in November to push the yearly rate of inflation to a 39-year high of 6.8%<a href=\"https://www.marketwatch.com/story/americans-pay-the-price-for-high-inflation-each-time-they-go-to-the-grocery-store-11639155038?mod=economic-report&mod=article_inline\" target=\"_blank\">.</a> Adjusted for inflation retail sales appeared to have declined.</p>\n<p><b>Big picture:</b> Americans have lots to spend because of stimulus money, rising wages and high savings amassed during the pandemic. But surging inflation might make them rethink what they buy.</p>\n<p>The big danger is if high inflation persists and price increases become embedded in the economy. That could force the Federal Reserve to jack up interest rates, further raise business costs and discourage consumers from buying as many goods and services.</p>\n<p>The Fed still believes inflation will cool off in 2022, but the central bank is worried enough to phase out stimulus for the economy a lot faster than it had planned.</p>\n<p><b>Market reaction:</b> The Dow Jones Industrial Average and S&P 500 were set to open slightly lower in Wednesday trades.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. retail sales climb tepid 0.3% in November as Americans confront high inflation </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. retail sales climb tepid 0.3% in November as Americans confront high inflation \n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-15 21:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>The numbers:</b> Amazon, Target and other retailers posted a small 0.3% increase in sales in November at the start of the holiday season, but if high inflation is taken into account, receipts fell in a weak showing for the economy.</p>\n<p></p>\n<p>Economists polled by The Wall Street Journal had forecast a 0.8% increase.</p>\n<p>The increase in sales was outstripped by a rising cost of living. The consumer price index jumped 0.8% in November to push the yearly rate of inflation to a 39-year high of 6.8%<a href=\"https://www.marketwatch.com/story/americans-pay-the-price-for-high-inflation-each-time-they-go-to-the-grocery-store-11639155038?mod=economic-report&mod=article_inline\" target=\"_blank\">.</a> Adjusted for inflation retail sales appeared to have declined.</p>\n<p><b>Big picture:</b> Americans have lots to spend because of stimulus money, rising wages and high savings amassed during the pandemic. But surging inflation might make them rethink what they buy.</p>\n<p>The big danger is if high inflation persists and price increases become embedded in the economy. That could force the Federal Reserve to jack up interest rates, further raise business costs and discourage consumers from buying as many goods and services.</p>\n<p>The Fed still believes inflation will cool off in 2022, but the central bank is worried enough to phase out stimulus for the economy a lot faster than it had planned.</p>\n<p><b>Market reaction:</b> The Dow Jones Industrial Average and S&P 500 were set to open slightly lower in Wednesday trades.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148643584","content_text":"The numbers: Amazon, Target and other retailers posted a small 0.3% increase in sales in November at the start of the holiday season, but if high inflation is taken into account, receipts fell in a weak showing for the economy.\n\nEconomists polled by The Wall Street Journal had forecast a 0.8% increase.\nThe increase in sales was outstripped by a rising cost of living. The consumer price index jumped 0.8% in November to push the yearly rate of inflation to a 39-year high of 6.8%. Adjusted for inflation retail sales appeared to have declined.\nBig picture: Americans have lots to spend because of stimulus money, rising wages and high savings amassed during the pandemic. But surging inflation might make them rethink what they buy.\nThe big danger is if high inflation persists and price increases become embedded in the economy. That could force the Federal Reserve to jack up interest rates, further raise business costs and discourage consumers from buying as many goods and services.\nThe Fed still believes inflation will cool off in 2022, but the central bank is worried enough to phase out stimulus for the economy a lot faster than it had planned.\nMarket reaction: The Dow Jones Industrial Average and S&P 500 were set to open slightly lower in Wednesday trades.","news_type":1},"isVote":1,"tweetType":1,"viewCount":690,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604535094,"gmtCreate":1639409933242,"gmtModify":1639411184498,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Oh my con","listText":"Oh my con","text":"Oh my con","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604535094","repostId":"1167465214","repostType":4,"repost":{"id":"1167465214","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639406352,"share":"https://www.laohu8.com/m/news/1167465214?lang=&edition=full","pubTime":"2021-12-13 22:39","market":"us","language":"en","title":"Arena Pharmaceuticals jumped over 80% in morning trading as Pfizer acquired it for US $100/share","url":"https://stock-news.laohu8.com/highlight/detail?id=1167465214","media":"Tiger Newspress","summary":"Arena Pharmaceuticals jumped over 80% in morning trading as Pfizer acquired it for US $100/share.Pfi","content":"<p>Arena Pharmaceuticals jumped over 80% in morning trading as Pfizer acquired it for US $100/share.<img src=\"https://static.tigerbbs.com/baca4cde05c414b1c77aa618108489b1\" tg-width=\"774\" tg-height=\"568\" width=\"100%\" height=\"auto\">Pfizer Inc has agreed to acquire Arena Pharmaceuticals in a $6.7 billion all-cash deal to expand its cancer and inflammatory disease treatment pipeline, the companies said on Monday.</p>\n<p>Pfizer will take over all outstanding shares of Arena for $100 per share, representing a 100.2% premium to Arena's last closing price.</p>\n<p>Arena is developing several treatments for gastroenterology, dermatology, and cardiology. The drug developer's ulcerative colitis treatment candidate, etrasimod, is in a late-stage study.</p>\n<p>Pfizer said it expects to finance the transaction with cash on hand.</p>\n<p>Pfizer’s financial advisers for the transaction are BofA Securities and Centerview Partners LLC, while Guggenheim Securities LLC and Evercore Group LLC advised Arena.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arena Pharmaceuticals jumped over 80% in morning trading as Pfizer acquired it for US $100/share</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArena Pharmaceuticals jumped over 80% in morning trading as Pfizer acquired it for US $100/share\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-13 22:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Arena Pharmaceuticals jumped over 80% in morning trading as Pfizer acquired it for US $100/share.<img src=\"https://static.tigerbbs.com/baca4cde05c414b1c77aa618108489b1\" tg-width=\"774\" tg-height=\"568\" width=\"100%\" height=\"auto\">Pfizer Inc has agreed to acquire Arena Pharmaceuticals in a $6.7 billion all-cash deal to expand its cancer and inflammatory disease treatment pipeline, the companies said on Monday.</p>\n<p>Pfizer will take over all outstanding shares of Arena for $100 per share, representing a 100.2% premium to Arena's last closing price.</p>\n<p>Arena is developing several treatments for gastroenterology, dermatology, and cardiology. The drug developer's ulcerative colitis treatment candidate, etrasimod, is in a late-stage study.</p>\n<p>Pfizer said it expects to finance the transaction with cash on hand.</p>\n<p>Pfizer’s financial advisers for the transaction are BofA Securities and Centerview Partners LLC, while Guggenheim Securities LLC and Evercore Group LLC advised Arena.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARNA":"阿里那","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167465214","content_text":"Arena Pharmaceuticals jumped over 80% in morning trading as Pfizer acquired it for US $100/share.Pfizer Inc has agreed to acquire Arena Pharmaceuticals in a $6.7 billion all-cash deal to expand its cancer and inflammatory disease treatment pipeline, the companies said on Monday.\nPfizer will take over all outstanding shares of Arena for $100 per share, representing a 100.2% premium to Arena's last closing price.\nArena is developing several treatments for gastroenterology, dermatology, and cardiology. The drug developer's ulcerative colitis treatment candidate, etrasimod, is in a late-stage study.\nPfizer said it expects to finance the transaction with cash on hand.\nPfizer’s financial advisers for the transaction are BofA Securities and Centerview Partners LLC, while Guggenheim Securities LLC and Evercore Group LLC advised Arena.","news_type":1},"isVote":1,"tweetType":1,"viewCount":652,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605500439,"gmtCreate":1639186173290,"gmtModify":1639186174334,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605500439","repostId":"1199826178","repostType":4,"repost":{"id":"1199826178","pubTimestamp":1639149380,"share":"https://www.laohu8.com/m/news/1199826178?lang=&edition=full","pubTime":"2021-12-10 23:16","market":"us","language":"en","title":"Hedge Funds Ensnared in Expansive DOJ Probe Into Short Selling","url":"https://stock-news.laohu8.com/highlight/detail?id=1199826178","media":"Bloomberg","summary":"Funds and researchers are scrutinized by Justice Department. Inquiry seeks information on trading in several dozen stocks. The U.S. Justice Department has launched an expansive criminal investigation into short selling by hedge funds and research firms, scrutinizing their symbiotic relationships and hunting for signs that they improperly coordinated trades or broke other laws to profit, according to people familiar with the matter.The probe, run by the department’s fraud section with federal pro","content":"<ul>\n <li>Funds and researchers are scrutinized by Justice Department</li>\n <li>Inquiry seeks information on trading in several dozen stocks</li>\n</ul>\n<p>The U.S. Justice Department has launched an expansive criminal investigation into short selling by hedge funds and research firms, scrutinizing their symbiotic relationships and hunting for signs that they improperly coordinated trades or broke other laws to profit, according to people familiar with the matter.</p>\n<p>The probe, run by the department’s fraud section with federal prosecutors in Los Angeles, is digging into how hedge funds tap into research and set up their bets, especially in the run-up to publication of reports that move stocks.</p>\n<p>Authorities are prying into financial relationships between hedge funds and researchers, and hunting for signs that money managers sought to engineer startling stock drops or engaged in other abuses, such as insider trading, said two of the people, asking not to be named because the inquiries are confidential.</p>\n<p>Underscoring the inquiry’s sweep, federal investigators are examining trading in at least several dozen stocks, including well-known short targets such as Luckin Coffee Inc.,Banc of California Inc.,Mallinckrodt Plc and GSX Techedu Inc.And they’re scrutinizing the involvement of about a dozen or more firms -- though it’s not clear which ones, if any, may emerge as targets of the probe. Toronto-based Anson Funds and anonymous researcher Marcus Aurelius Value are among firms involved in the inquiry, the people said. Other prominent firms that circulated research on stocks under scrutiny include Carson Block’s Muddy Waters Capital and Andrew Left’s Citron Research.</p>\n<p>The U.S. probe opens yet another front in an already treacherous era for those who try to profit on stock drops. Some bearish funds threw in the towel as government stimulus buoyed prices during the pandemic. That pressure intensified as retail investors organized counterattacks on popular short targets, bidding up shares to inflictlosseson hedge funds this year. By late January, Citron vowed to give up short-selling research and focus on long bets.</p>\n<p>Meanwhile, companies criticized by short sellers have become increasingly bold in firing back, sometimes launching legal battles even as they face government probes that ultimately support short sellers’ theses. A number of corporate executives have been hoping U.S. authorities might help to further shift the focus to investors’ tactics.</p>\n<p>Still, successfully bringing charges against short sellers could be challenging, given that betting against companies and publishing research believed to be accurate is lawful and even beneficial for markets. So far, nobody has been accused of wrongdoing, and authorities may ultimately decide not to pursue charges.</p>\n<p>Government attorneys are trying to determine whether short sellers engaged in some form of deception -- say, by misleading the public about their financing of what appears to be independent research, violating confidentiality agreements with authors, or orchestrating stock plunges to panic shareholders and exacerbate selling.</p>\n<p>Spokespeople for the Justice Department and Muddy Waters declined to comment, and there was no response to messages sent to Anson Funds and Aurelius.</p>\n<p>An attorney for Citron said he’s aware of an industry probe but that it’s routine for U.S. investigators to open and close cases. He expressed doubt that their theories would be borne out.</p>\n<p>“Citron Capital and Mr. Left are successful because they do quality research and keep their reports secret from other short sellers until publication,” said the lawyer, James Spertus. “There is simply no truth behind any theory that short sellers coordinate amongst themselves before publishing reports, at least in regard to publications by Citron Capital and Andrew Left. I am hopeful that anyone investigating the issue will reach that conclusion as soon as possible.”</p>\n<p><b>Funding Research</b></p>\n<p>Hedge funds are known to strike a wide variety of deals with researchers, sometimes paying handsome subscription fees for fresh insights into possible corporate trouble, or even becoming an author’s primary source of funding. In one example, prominent financial investigator Harry Markopolos, who normally makes money from whistle-blower awards,said he partnered with a hedge fund to share profits when he released a report on General Electric Co.</p>\n<p>Some hedge funds have been known to suggest targets to researchers, who then deliver scathing reports.</p>\n<p>One cautionary tale emerged in court after Dallas-based Sabrepoint Capital agreed to pay a short-selling researcher a monthly retainer of $9,500 in 2018. Sabrepoint encouraged him to dig into real estate company Farmland Partners Inc.The researcher, who also wrote publicly under a pseudonym, later published an article on Seeking Alpha, setting off a 39% drop in Farmland’s share price. The company sued and used a judge’s order to force him to reveal his identity: Quinton Mathews.</p>\n<p>Mathews later said in a statement that he subsequently learned his article “contained inaccuracies and false allegations” and retracted it. He and Farmland reached a settlement. Sabrepoint has said it didn’t know about the Seeking Alpha article.</p>\n<p>Farmland also is on the list of stocks that the Justice Department is examining. Lawyers for Sabrepoint and Mathews declined to comment.</p>\n<p>The Justice Department unit handling the inquiry already has a formidable reputation on Wall Street. It recently brought several cases against global banks and traders for illegal spoofing of precious metals and Treasury futures. As part of that probe,JPMorgan Chase & Co. paid more than $900 million in penalties after its traders placed and canceled orders for commodities to benefit positions held by the bank or prized hedge fund clients. Those cases were brought by analyzing trading data for suspicious patterns and then attributing it to individual traders.</p>\n<p>While prosecutors in the short-selling investigation issued subpoenas as recently as October, the effort has been underway much longer, the people said.</p>\n<p>The inquiry gained momentum after U.S. lawmakers called for more scrutiny of short sellers following the so-called meme-stock trading frenzy that erupted in January. In a single week that month, retail investors sent the price of GameStop Corp. soaring more than 700% before brokerages began limiting bets. Some organizers of the buying spree claimed hedge funds had been unfairly using their market clout to drive down stocks.</p>\n<p>Lawmakers have since held multiple hearings on the fracas, at times discussing whether to force short sellers to boost disclosures.</p>\n<p>Concerns about how short sellers carry out attacks have arisen repeatedly over the years.</p>\n<p>The Securities and Exchange Commission and Justice Department have gone after hedge funds for running “short and distort” campaigns. The practice typically involves setting up bearish bets, then releasing misleading or inaccurate information about a company to drive down the price before closing out the position for a profit.</p>\n<p>But there are also concerns about the impact that earnest research can have when it’s sprung by surprise on the market.</p>\n<p>Studies by Columbia University law professor Joshua Mitts have found that short sellers’ reports can briefly induce bouts of panic selling before shares rebound. In those jittery moments -- sometimes mere minutes or hours -- well-positioned short sellers can cash out of trades and pocket significant gains.</p>\n<p>Mitts examined more than 1,700 reports made by pseudonymous short sellers from 2010 to 2017, concluding that they contributed to more than $20 billion in dislocated values or temporarily mispriced stocks.</p>\n<p>Academics have been encouraging U.S. authorities to address the possibility that short sellers are laying out their cases against stocks, then using the impact of that news to quickly reap gains and quietly move on.</p>\n<p>Early last year, Mitts and about a dozen other prominent securities-law professors urged the SEC to write rules requiring that short sellers who voluntarily reveal bets against a stock be required to disclose when they’ve exited the position. The professors also asked the regulator to write a new rule that would make closing a short position immediately after disseminating a negative report -- with an intent to do so upon publication -- constitute market manipulation.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hedge Funds Ensnared in Expansive DOJ Probe Into Short Selling</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHedge Funds Ensnared in Expansive DOJ Probe Into Short Selling\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-10 23:16 GMT+8 <a href=https://www.bloomberg.com/news/articles/2021-12-10/hedge-funds-ensnared-in-expansive-doj-probe-into-short-selling?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Funds and researchers are scrutinized by Justice Department\nInquiry seeks information on trading in several dozen stocks\n\nThe U.S. Justice Department has launched an expansive criminal investigation ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-10/hedge-funds-ensnared-in-expansive-doj-probe-into-short-selling?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BANC":"BANC OF CALIFORNIA","GME":"游戏驿站",".DJI":"道琼斯","GOTU":"高途","LKNCY":"瑞幸咖啡","MNKKQ":"Mallinckrodt plc.","FPI":"Farmland Partners Inc","GE":"GE航空航天",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://www.bloomberg.com/news/articles/2021-12-10/hedge-funds-ensnared-in-expansive-doj-probe-into-short-selling?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199826178","content_text":"Funds and researchers are scrutinized by Justice Department\nInquiry seeks information on trading in several dozen stocks\n\nThe U.S. Justice Department has launched an expansive criminal investigation into short selling by hedge funds and research firms, scrutinizing their symbiotic relationships and hunting for signs that they improperly coordinated trades or broke other laws to profit, according to people familiar with the matter.\nThe probe, run by the department’s fraud section with federal prosecutors in Los Angeles, is digging into how hedge funds tap into research and set up their bets, especially in the run-up to publication of reports that move stocks.\nAuthorities are prying into financial relationships between hedge funds and researchers, and hunting for signs that money managers sought to engineer startling stock drops or engaged in other abuses, such as insider trading, said two of the people, asking not to be named because the inquiries are confidential.\nUnderscoring the inquiry’s sweep, federal investigators are examining trading in at least several dozen stocks, including well-known short targets such as Luckin Coffee Inc.,Banc of California Inc.,Mallinckrodt Plc and GSX Techedu Inc.And they’re scrutinizing the involvement of about a dozen or more firms -- though it’s not clear which ones, if any, may emerge as targets of the probe. Toronto-based Anson Funds and anonymous researcher Marcus Aurelius Value are among firms involved in the inquiry, the people said. Other prominent firms that circulated research on stocks under scrutiny include Carson Block’s Muddy Waters Capital and Andrew Left’s Citron Research.\nThe U.S. probe opens yet another front in an already treacherous era for those who try to profit on stock drops. Some bearish funds threw in the towel as government stimulus buoyed prices during the pandemic. That pressure intensified as retail investors organized counterattacks on popular short targets, bidding up shares to inflictlosseson hedge funds this year. By late January, Citron vowed to give up short-selling research and focus on long bets.\nMeanwhile, companies criticized by short sellers have become increasingly bold in firing back, sometimes launching legal battles even as they face government probes that ultimately support short sellers’ theses. A number of corporate executives have been hoping U.S. authorities might help to further shift the focus to investors’ tactics.\nStill, successfully bringing charges against short sellers could be challenging, given that betting against companies and publishing research believed to be accurate is lawful and even beneficial for markets. So far, nobody has been accused of wrongdoing, and authorities may ultimately decide not to pursue charges.\nGovernment attorneys are trying to determine whether short sellers engaged in some form of deception -- say, by misleading the public about their financing of what appears to be independent research, violating confidentiality agreements with authors, or orchestrating stock plunges to panic shareholders and exacerbate selling.\nSpokespeople for the Justice Department and Muddy Waters declined to comment, and there was no response to messages sent to Anson Funds and Aurelius.\nAn attorney for Citron said he’s aware of an industry probe but that it’s routine for U.S. investigators to open and close cases. He expressed doubt that their theories would be borne out.\n“Citron Capital and Mr. Left are successful because they do quality research and keep their reports secret from other short sellers until publication,” said the lawyer, James Spertus. “There is simply no truth behind any theory that short sellers coordinate amongst themselves before publishing reports, at least in regard to publications by Citron Capital and Andrew Left. I am hopeful that anyone investigating the issue will reach that conclusion as soon as possible.”\nFunding Research\nHedge funds are known to strike a wide variety of deals with researchers, sometimes paying handsome subscription fees for fresh insights into possible corporate trouble, or even becoming an author’s primary source of funding. In one example, prominent financial investigator Harry Markopolos, who normally makes money from whistle-blower awards,said he partnered with a hedge fund to share profits when he released a report on General Electric Co.\nSome hedge funds have been known to suggest targets to researchers, who then deliver scathing reports.\nOne cautionary tale emerged in court after Dallas-based Sabrepoint Capital agreed to pay a short-selling researcher a monthly retainer of $9,500 in 2018. Sabrepoint encouraged him to dig into real estate company Farmland Partners Inc.The researcher, who also wrote publicly under a pseudonym, later published an article on Seeking Alpha, setting off a 39% drop in Farmland’s share price. The company sued and used a judge’s order to force him to reveal his identity: Quinton Mathews.\nMathews later said in a statement that he subsequently learned his article “contained inaccuracies and false allegations” and retracted it. He and Farmland reached a settlement. Sabrepoint has said it didn’t know about the Seeking Alpha article.\nFarmland also is on the list of stocks that the Justice Department is examining. Lawyers for Sabrepoint and Mathews declined to comment.\nThe Justice Department unit handling the inquiry already has a formidable reputation on Wall Street. It recently brought several cases against global banks and traders for illegal spoofing of precious metals and Treasury futures. As part of that probe,JPMorgan Chase & Co. paid more than $900 million in penalties after its traders placed and canceled orders for commodities to benefit positions held by the bank or prized hedge fund clients. Those cases were brought by analyzing trading data for suspicious patterns and then attributing it to individual traders.\nWhile prosecutors in the short-selling investigation issued subpoenas as recently as October, the effort has been underway much longer, the people said.\nThe inquiry gained momentum after U.S. lawmakers called for more scrutiny of short sellers following the so-called meme-stock trading frenzy that erupted in January. In a single week that month, retail investors sent the price of GameStop Corp. soaring more than 700% before brokerages began limiting bets. Some organizers of the buying spree claimed hedge funds had been unfairly using their market clout to drive down stocks.\nLawmakers have since held multiple hearings on the fracas, at times discussing whether to force short sellers to boost disclosures.\nConcerns about how short sellers carry out attacks have arisen repeatedly over the years.\nThe Securities and Exchange Commission and Justice Department have gone after hedge funds for running “short and distort” campaigns. The practice typically involves setting up bearish bets, then releasing misleading or inaccurate information about a company to drive down the price before closing out the position for a profit.\nBut there are also concerns about the impact that earnest research can have when it’s sprung by surprise on the market.\nStudies by Columbia University law professor Joshua Mitts have found that short sellers’ reports can briefly induce bouts of panic selling before shares rebound. In those jittery moments -- sometimes mere minutes or hours -- well-positioned short sellers can cash out of trades and pocket significant gains.\nMitts examined more than 1,700 reports made by pseudonymous short sellers from 2010 to 2017, concluding that they contributed to more than $20 billion in dislocated values or temporarily mispriced stocks.\nAcademics have been encouraging U.S. authorities to address the possibility that short sellers are laying out their cases against stocks, then using the impact of that news to quickly reap gains and quietly move on.\nEarly last year, Mitts and about a dozen other prominent securities-law professors urged the SEC to write rules requiring that short sellers who voluntarily reveal bets against a stock be required to disclose when they’ve exited the position. The professors also asked the regulator to write a new rule that would make closing a short position immediately after disseminating a negative report -- with an intent to do so upon publication -- constitute market manipulation.","news_type":1},"isVote":1,"tweetType":1,"viewCount":905,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605500663,"gmtCreate":1639186160836,"gmtModify":1639186161876,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"✅ ","listText":"✅ ","text":"✅","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605500663","repostId":"2190767366","repostType":4,"repost":{"id":"2190767366","pubTimestamp":1639171676,"share":"https://www.laohu8.com/m/news/2190767366?lang=&edition=full","pubTime":"2021-12-11 05:27","market":"hk","language":"en","title":"US STOCKS-Wall Street gains, S&P hits record closing high as CPI meets expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2190767366","media":"Reuters","summary":"(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news","content":"<p>(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.)</p>\n<p>* Annual CPI growth hits highest level in more than 39 years</p>\n<p>* S&P registers biggest weekly percentage gain since Feb</p>\n<p>* Oracle leaps on upbeat quarterly results, outlook</p>\n<p>* Broadcom gains on buyback plan announcement</p>\n<p>* Indexes up: Dow 0.60%, S&P 0.95%, Nasdaq 0.73% (Updates with closing prices, adds market details)</p>\n<p>NEW YORK, Dec 10 (Reuters) - Wall Street advanced on Friday and the S&P 500 notched an all-time closing high, as market participants digested an inflation reading that was in line with consensus, but also marked the largest annual increase in consumer prices in nearly four decades.</p>\n<p>All three major U.S. stock indexes advanced, with tech shares doing the heavy lifting.</p>\n<p>The indexes all ended the session higher than last Friday's close, and the benchmark S&P 500 posted its biggest weekly percentage advance since the week ended Feb. 5, as waning jitters over the Omicron coronavirus variant helped fuel a broad rally early in the week.</p>\n<p>A report from the Labor Department showed consumer prices surged last month to a 6.8% annual growth rate, the highest reading in more than 39 years.</p>\n<p>\"It would appear that today’s reaction would indicate the markets were discounting the (CPI) reading,\" said Chuck Carlson, chief executive officer at Horizon Investment Services in Hammond, Indiana. \"The markets are always looking forward and perhaps today's reading is indicative of a peak versus a sustained level.\"</p>\n<p>Persistent inflation due to ongoing supply-chain challenges suggests the U.S. Federal Reserve could very well start tightening its accommodative monetary policy sooner than many might have hoped.</p>\n<p>\"Clearly, it’s being driven primarily by supply-chain issues,\" Said Tim Ghriskey, senior portfolio strategist at Inverness Counsel in New York. \"But it appears these issues could be easing, and over time we should see them moderate. And that should take the foot off the inflation accelerator.\"</p>\n<p>A Reuters poll of economists sees the central bank hiking key interest rates from near zero to 0.25-0.50% in the third quarter of next year, followed by another in the fourth quarter.</p>\n<p>The Fed is expected to convene next week for its two-day monetary policy meeting, which market participants will be scrutinizing for any clues regarding those rate increases along with the pace at which it will taper its bond purchases.</p>\n<p>\"The Fed is has telegraphed on tightening sooner rather than later,\" Carlson added. \"The markets are more comfortable with Fed tightening if it reduces inflation expectations.\"</p>\n<p>The graphic below shows core CPI along with other major U.S. indicators, all of which continue to soar well above the Fed's average annual 2% inflation target:</p>\n<p>The Dow Jones Industrial Average rose 216.3 points, or 0.6%, to 35,970.99, the S&P 500 gained 44.57 points, or 0.95%, to 4,712.02 and the Nasdaq Composite added 113.23 points, or 0.73%, to 15,630.60.</p>\n<p>All 11 major sectors in the S&P 500 ended the session green, with technology and consumer staples enjoying the largest percentage jumps.</p>\n<p>Shares of software firm Oracle Corp jumped 15.6% after it forecast an upbeat third-quarter outlook.</p>\n<p>Broadcom Inc gained 8.3% following the chipmaker's announcement of a $10 billion share buyback plan.</p>\n<p>Elon Musk, chief executive of Tesla Inc, tweeted that he is \"thinking of quitting my jobs & becoming an influencer full-time.\" The electric car maker's stock advanced 1.3%.</p>\n<p>Southwest Airlines dropped 3.8% after Goldman Sachs downgraded the commercial air carrier's shares to \"sell\" from \"neutral.\"</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.05-to-1 ratio; on Nasdaq, a 1.48-to-1 ratio favored decliners.</p>\n<p>The S&P 500 posted 38 new 52-week highs and <a href=\"https://laohu8.com/S/AONE.U\">one</a> new low; the Nasdaq Composite recorded 34 new highs and 155 new lows.</p>\n<p>Volume on U.S. exchanges was 9.60 billion shares, compared with the 11.42 billion average over the last 20 trading days.</p>\n<p>(Reporting by Stephen Culp in New York Additional reporting by Devik Jain, Shreyashi Sanyal and Bansari Mayur Kamdar in Bengaluru Editing by Matthew Lewis)</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US STOCKS-Wall Street gains, S&P hits record closing high as CPI meets expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS STOCKS-Wall Street gains, S&P hits record closing high as CPI meets expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-11 05:27 GMT+8 <a href=https://finance.yahoo.com/news/us-stocks-wall-street-gains-212756605.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.)\n* Annual CPI growth hits highest level in more than 39 years\n* S&P registers biggest ...</p>\n\n<a href=\"https://finance.yahoo.com/news/us-stocks-wall-street-gains-212756605.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4539":"次新股","COMP":"Compass, Inc.","CPI":"IQ Real Return ETF",".IXIC":"NASDAQ Composite","BK4079":"房地产服务",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://finance.yahoo.com/news/us-stocks-wall-street-gains-212756605.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2190767366","content_text":"(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.)\n* Annual CPI growth hits highest level in more than 39 years\n* S&P registers biggest weekly percentage gain since Feb\n* Oracle leaps on upbeat quarterly results, outlook\n* Broadcom gains on buyback plan announcement\n* Indexes up: Dow 0.60%, S&P 0.95%, Nasdaq 0.73% (Updates with closing prices, adds market details)\nNEW YORK, Dec 10 (Reuters) - Wall Street advanced on Friday and the S&P 500 notched an all-time closing high, as market participants digested an inflation reading that was in line with consensus, but also marked the largest annual increase in consumer prices in nearly four decades.\nAll three major U.S. stock indexes advanced, with tech shares doing the heavy lifting.\nThe indexes all ended the session higher than last Friday's close, and the benchmark S&P 500 posted its biggest weekly percentage advance since the week ended Feb. 5, as waning jitters over the Omicron coronavirus variant helped fuel a broad rally early in the week.\nA report from the Labor Department showed consumer prices surged last month to a 6.8% annual growth rate, the highest reading in more than 39 years.\n\"It would appear that today’s reaction would indicate the markets were discounting the (CPI) reading,\" said Chuck Carlson, chief executive officer at Horizon Investment Services in Hammond, Indiana. \"The markets are always looking forward and perhaps today's reading is indicative of a peak versus a sustained level.\"\nPersistent inflation due to ongoing supply-chain challenges suggests the U.S. Federal Reserve could very well start tightening its accommodative monetary policy sooner than many might have hoped.\n\"Clearly, it’s being driven primarily by supply-chain issues,\" Said Tim Ghriskey, senior portfolio strategist at Inverness Counsel in New York. \"But it appears these issues could be easing, and over time we should see them moderate. And that should take the foot off the inflation accelerator.\"\nA Reuters poll of economists sees the central bank hiking key interest rates from near zero to 0.25-0.50% in the third quarter of next year, followed by another in the fourth quarter.\nThe Fed is expected to convene next week for its two-day monetary policy meeting, which market participants will be scrutinizing for any clues regarding those rate increases along with the pace at which it will taper its bond purchases.\n\"The Fed is has telegraphed on tightening sooner rather than later,\" Carlson added. \"The markets are more comfortable with Fed tightening if it reduces inflation expectations.\"\nThe graphic below shows core CPI along with other major U.S. indicators, all of which continue to soar well above the Fed's average annual 2% inflation target:\nThe Dow Jones Industrial Average rose 216.3 points, or 0.6%, to 35,970.99, the S&P 500 gained 44.57 points, or 0.95%, to 4,712.02 and the Nasdaq Composite added 113.23 points, or 0.73%, to 15,630.60.\nAll 11 major sectors in the S&P 500 ended the session green, with technology and consumer staples enjoying the largest percentage jumps.\nShares of software firm Oracle Corp jumped 15.6% after it forecast an upbeat third-quarter outlook.\nBroadcom Inc gained 8.3% following the chipmaker's announcement of a $10 billion share buyback plan.\nElon Musk, chief executive of Tesla Inc, tweeted that he is \"thinking of quitting my jobs & becoming an influencer full-time.\" The electric car maker's stock advanced 1.3%.\nSouthwest Airlines dropped 3.8% after Goldman Sachs downgraded the commercial air carrier's shares to \"sell\" from \"neutral.\"\nDeclining issues outnumbered advancing ones on the NYSE by a 1.05-to-1 ratio; on Nasdaq, a 1.48-to-1 ratio favored decliners.\nThe S&P 500 posted 38 new 52-week highs and one new low; the Nasdaq Composite recorded 34 new highs and 155 new lows.\nVolume on U.S. exchanges was 9.60 billion shares, compared with the 11.42 billion average over the last 20 trading days.\n(Reporting by Stephen Culp in New York Additional reporting by Devik Jain, Shreyashi Sanyal and Bansari Mayur Kamdar in Bengaluru Editing by Matthew Lewis)","news_type":1},"isVote":1,"tweetType":1,"viewCount":547,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605857916,"gmtCreate":1639147777266,"gmtModify":1639147778334,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605857916","repostId":"1100115506","repostType":4,"repost":{"id":"1100115506","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639138188,"share":"https://www.laohu8.com/m/news/1100115506?lang=&edition=full","pubTime":"2021-12-10 20:09","market":"us","language":"en","title":"Some vaccine stocks dropped in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1100115506","media":"Tiger Newspress","summary":"Some vaccine stocks dropped in premarket trading.Moderna fell more than 6%,BioNTech and Novavax fell","content":"<p>Some vaccine stocks dropped in premarket trading.Moderna fell more than 6%,BioNTech and Novavax fell about 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/8a520d484bb38c42dea515aeca96c8b3\" tg-width=\"843\" tg-height=\"623\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/3f4e9ce656bcb771198057d217489677\" tg-width=\"843\" tg-height=\"618\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/fd626ba47bec50af63916a31695eca4c\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some vaccine stocks dropped in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome vaccine stocks dropped in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-10 20:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Some vaccine stocks dropped in premarket trading.Moderna fell more than 6%,BioNTech and Novavax fell about 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/8a520d484bb38c42dea515aeca96c8b3\" tg-width=\"843\" tg-height=\"623\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/3f4e9ce656bcb771198057d217489677\" tg-width=\"843\" tg-height=\"618\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/fd626ba47bec50af63916a31695eca4c\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100115506","content_text":"Some vaccine stocks dropped in premarket trading.Moderna fell more than 6%,BioNTech and Novavax fell about 2%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":642,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605854787,"gmtCreate":1639147765076,"gmtModify":1639147766866,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Down ","listText":"Down ","text":"Down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605854787","repostId":"1148141788","repostType":4,"isVote":1,"tweetType":1,"viewCount":463,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602484310,"gmtCreate":1639058002940,"gmtModify":1639058940759,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Go ","listText":"Go ","text":"Go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602484310","repostId":"1129645066","repostType":4,"repost":{"id":"1129645066","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639053071,"share":"https://www.laohu8.com/m/news/1129645066?lang=&edition=full","pubTime":"2021-12-09 20:31","market":"us","language":"en","title":"Amazon shares fell slightly by 0.5% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1129645066","media":"Tiger Newspress","summary":"Amazon shares fell slightly by 0.5% in premarket trading after Italy's antitrust fined Amazon 1.13 b","content":"<p>Amazon shares fell slightly by 0.5% in premarket trading after Italy's antitrust fined Amazon 1.13 bln euros for alleged abuse of market dominance.</p>\n<p><img src=\"https://static.tigerbbs.com/1aa0616746882964f5e05a784287edeb\" tg-width=\"850\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<p>Italy's antitrust said on Thursday it had fined e-commerce giant Amazon 1.13 billion euros ($1.28 billion) for alleged abuse of market dominance.</p>\n<p>In a statement the watchdog said Amazon had harmed competing operators in the e-commerce logistics service.</p>\n<p>\"Amazon holds a dominant position in the Italian market for intermediation services on marketplaces, which Amazon leveraged to favour the adoption of its own logistics service - Fulfilment by Amazon (FBA) - by sellers active on Amazon.it to the detriment of the logistics services offered by competing operators, as well as to strengthen its own dominant position,\" it added.</p>\n<p>The antitrust said it would impose on Amazon corrective steps that will be subject to review by a monitoring trustee.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon shares fell slightly by 0.5% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon shares fell slightly by 0.5% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-09 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Amazon shares fell slightly by 0.5% in premarket trading after Italy's antitrust fined Amazon 1.13 bln euros for alleged abuse of market dominance.</p>\n<p><img src=\"https://static.tigerbbs.com/1aa0616746882964f5e05a784287edeb\" tg-width=\"850\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<p>Italy's antitrust said on Thursday it had fined e-commerce giant Amazon 1.13 billion euros ($1.28 billion) for alleged abuse of market dominance.</p>\n<p>In a statement the watchdog said Amazon had harmed competing operators in the e-commerce logistics service.</p>\n<p>\"Amazon holds a dominant position in the Italian market for intermediation services on marketplaces, which Amazon leveraged to favour the adoption of its own logistics service - Fulfilment by Amazon (FBA) - by sellers active on Amazon.it to the detriment of the logistics services offered by competing operators, as well as to strengthen its own dominant position,\" it added.</p>\n<p>The antitrust said it would impose on Amazon corrective steps that will be subject to review by a monitoring trustee.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129645066","content_text":"Amazon shares fell slightly by 0.5% in premarket trading after Italy's antitrust fined Amazon 1.13 bln euros for alleged abuse of market dominance.\n\nItaly's antitrust said on Thursday it had fined e-commerce giant Amazon 1.13 billion euros ($1.28 billion) for alleged abuse of market dominance.\nIn a statement the watchdog said Amazon had harmed competing operators in the e-commerce logistics service.\n\"Amazon holds a dominant position in the Italian market for intermediation services on marketplaces, which Amazon leveraged to favour the adoption of its own logistics service - Fulfilment by Amazon (FBA) - by sellers active on Amazon.it to the detriment of the logistics services offered by competing operators, as well as to strengthen its own dominant position,\" it added.\nThe antitrust said it would impose on Amazon corrective steps that will be subject to review by a monitoring trustee.","news_type":1},"isVote":1,"tweetType":1,"viewCount":584,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602915546,"gmtCreate":1638956253196,"gmtModify":1638956689133,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Woo","listText":"Woo","text":"Woo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602915546","repostId":"1136716851","repostType":4,"isVote":1,"tweetType":1,"viewCount":602,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606504712,"gmtCreate":1638890080088,"gmtModify":1638890089373,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"999","listText":"999","text":"999","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606504712","repostId":"1107798974","repostType":4,"repost":{"id":"1107798974","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638889130,"share":"https://www.laohu8.com/m/news/1107798974?lang=&edition=full","pubTime":"2021-12-07 22:58","market":"us","language":"en","title":"777 Partners Orders 30 Additional 737 MAX Airplanes","url":"https://stock-news.laohu8.com/highlight/detail?id=1107798974","media":"Tiger Newspress","summary":"Boeing's stock extends bounce after receiving additional order for 30 737 MAX jets from 777 Partners","content":"<p>Boeing's stock extends bounce after receiving additional order for 30 737 MAX jets from 777 Partners.</p>\n<p><img src=\"https://static.tigerbbs.com/c0a9ddf262204e94020bb4a124cc1b01\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>Boeing and 777 Partners today announced the Miami-based investment firm will nearly double its 737 MAX order book with the purchase of 30 additional jets. The new order expands 777 Partners' commercial aircraft portfolio to a total of 68 737 MAXs, in its fourth order this year for the fuel-efficient, single-aisle jets. Valued at $3.7 billion at list prices, the order will enable 777 Partners to expand 737 MAX operations across the fleet of its affiliated global low-cost carriers.</p>\n<p>\"We're delighted to be able to announce the almost doubling in size of our order with Boeing,\" said Josh Wander, managing partner of 777 Partners. \"We have long been confident in the economics of the 737 MAX family but we are especially excited about the 737-8-200 variant which represents the bulk of our additional orders. We're confident that this aircraft will be the hallmark ULCC/LCC asset, particularly in the sub-200 seat market. As travel demand returns, 777 has accelerated our quest for efficiencies in both operating cost and carbon footprint at our operating carriers. . In these areas the 737-8 is compelling and the 737-8-200 is simply unrivalled.\"</p>\n<p>The 737 MAX family reduces fuel use and carbon emissions by at least 14% compared to the airplanes it replaces, reducing operating costs as well as the environmental footprint for 777 Partners' affiliated airlines. Every 737 MAX features a passenger-pleasing Boeing Sky Interior, highlighted by modern sculpted sidewalls and window reveals, LED lighting that enhances the sense of spaciousness and larger pivoting overhead storage bins.</p>\n<p>\"We greatly appreciate 777 Partners for their trust in our products, including repeat orders for the 737 MAX and expanding their fleet to include the high-capacity 737-8-200 model,\" said Ihssane Mounir, Boeing senior vice president of Commercial Sales and Marketing. \"777 Partners is enabling growth for its affiliated low-cost carriers by leveraging the 737 family's flexibility, reliability and efficiency to serve passengers for years to come.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>777 Partners Orders 30 Additional 737 MAX Airplanes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n777 Partners Orders 30 Additional 737 MAX Airplanes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-07 22:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Boeing's stock extends bounce after receiving additional order for 30 737 MAX jets from 777 Partners.</p>\n<p><img src=\"https://static.tigerbbs.com/c0a9ddf262204e94020bb4a124cc1b01\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>Boeing and 777 Partners today announced the Miami-based investment firm will nearly double its 737 MAX order book with the purchase of 30 additional jets. The new order expands 777 Partners' commercial aircraft portfolio to a total of 68 737 MAXs, in its fourth order this year for the fuel-efficient, single-aisle jets. Valued at $3.7 billion at list prices, the order will enable 777 Partners to expand 737 MAX operations across the fleet of its affiliated global low-cost carriers.</p>\n<p>\"We're delighted to be able to announce the almost doubling in size of our order with Boeing,\" said Josh Wander, managing partner of 777 Partners. \"We have long been confident in the economics of the 737 MAX family but we are especially excited about the 737-8-200 variant which represents the bulk of our additional orders. We're confident that this aircraft will be the hallmark ULCC/LCC asset, particularly in the sub-200 seat market. As travel demand returns, 777 has accelerated our quest for efficiencies in both operating cost and carbon footprint at our operating carriers. . In these areas the 737-8 is compelling and the 737-8-200 is simply unrivalled.\"</p>\n<p>The 737 MAX family reduces fuel use and carbon emissions by at least 14% compared to the airplanes it replaces, reducing operating costs as well as the environmental footprint for 777 Partners' affiliated airlines. Every 737 MAX features a passenger-pleasing Boeing Sky Interior, highlighted by modern sculpted sidewalls and window reveals, LED lighting that enhances the sense of spaciousness and larger pivoting overhead storage bins.</p>\n<p>\"We greatly appreciate 777 Partners for their trust in our products, including repeat orders for the 737 MAX and expanding their fleet to include the high-capacity 737-8-200 model,\" said Ihssane Mounir, Boeing senior vice president of Commercial Sales and Marketing. \"777 Partners is enabling growth for its affiliated low-cost carriers by leveraging the 737 family's flexibility, reliability and efficiency to serve passengers for years to come.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BA":"波音"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107798974","content_text":"Boeing's stock extends bounce after receiving additional order for 30 737 MAX jets from 777 Partners.\n\nBoeing and 777 Partners today announced the Miami-based investment firm will nearly double its 737 MAX order book with the purchase of 30 additional jets. The new order expands 777 Partners' commercial aircraft portfolio to a total of 68 737 MAXs, in its fourth order this year for the fuel-efficient, single-aisle jets. Valued at $3.7 billion at list prices, the order will enable 777 Partners to expand 737 MAX operations across the fleet of its affiliated global low-cost carriers.\n\"We're delighted to be able to announce the almost doubling in size of our order with Boeing,\" said Josh Wander, managing partner of 777 Partners. \"We have long been confident in the economics of the 737 MAX family but we are especially excited about the 737-8-200 variant which represents the bulk of our additional orders. We're confident that this aircraft will be the hallmark ULCC/LCC asset, particularly in the sub-200 seat market. As travel demand returns, 777 has accelerated our quest for efficiencies in both operating cost and carbon footprint at our operating carriers. . In these areas the 737-8 is compelling and the 737-8-200 is simply unrivalled.\"\nThe 737 MAX family reduces fuel use and carbon emissions by at least 14% compared to the airplanes it replaces, reducing operating costs as well as the environmental footprint for 777 Partners' affiliated airlines. Every 737 MAX features a passenger-pleasing Boeing Sky Interior, highlighted by modern sculpted sidewalls and window reveals, LED lighting that enhances the sense of spaciousness and larger pivoting overhead storage bins.\n\"We greatly appreciate 777 Partners for their trust in our products, including repeat orders for the 737 MAX and expanding their fleet to include the high-capacity 737-8-200 model,\" said Ihssane Mounir, Boeing senior vice president of Commercial Sales and Marketing. \"777 Partners is enabling growth for its affiliated low-cost carriers by leveraging the 737 family's flexibility, reliability and efficiency to serve passengers for years to come.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":567,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606504688,"gmtCreate":1638890062281,"gmtModify":1638890088126,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606504688","repostId":"2189476639","repostType":4,"repost":{"id":"2189476639","pubTimestamp":1638885035,"share":"https://www.laohu8.com/m/news/2189476639?lang=&edition=full","pubTime":"2021-12-07 21:50","market":"us","language":"en","title":"3 Dow Stocks Begging to Be Bought in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2189476639","media":"Motley Fool","summary":"Growth, value, and income investors all have a stock that's ripe for the picking.","content":"<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic <b>Dow Jones Industrial Average</b> (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.</p>\n<p>But just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/789196b3d59ea758b03121ea67790d5a\" tg-width=\"700\" tg-height=\"484\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a></h2>\n<p>For growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider <b>Salesforce.com</b> (NYSE:CRM).</p>\n<p>Like most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed <a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a> acquisition.</p>\n<p>While these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.</p>\n<p>CRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.</p>\n<p>Salesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.</p>\n<p>Growth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.</p>\n<p>With Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/467adad2d31104b83afa51e5b1425137\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Merck</h2>\n<p>Value investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock <b>Merck</b> (NYSE:MRK) are now begging to be bought.</p>\n<p>\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of <b>Pfizer</b>'s (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients. Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.</p>\n<p>But here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.</p>\n<p>The front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.</p>\n<p>The other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.</p>\n<p>Following its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb0880fa9f40b9af4d310e1390a18754\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Verizon</h2>\n<p>Finally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth <b>Verizon</b> (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.</p>\n<p>There look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.</p>\n<p>But similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.</p>\n<p>Despite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.</p>\n<p>The other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.</p>\n<p>Verizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dow Stocks Begging to Be Bought in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dow Stocks Begging to Be Bought in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 21:50 GMT+8 <a href=https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VZ":"威瑞森","BK4535":"淡马锡持仓","BK4559":"巴菲特持仓","BK4538":"云计算","BK4527":"明星科技股","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4115":"综合电信业务","CRM":"赛富时","BK4505":"高瓴资本持仓","BK4561":"索罗斯持仓","BK4548":"巴美列捷福持仓","MRK":"默沙东","BK4528":"SaaS概念","BK4516":"特朗普概念","BK4023":"应用软件","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4567":"ESG概念","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药"},"source_url":"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189476639","content_text":"As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.\nBut just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.\nImage source: Getty Images.\nSalesforce\nFor growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider Salesforce.com (NYSE:CRM).\nLike most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed Slack Technologies acquisition.\nWhile these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.\nCRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.\nSalesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.\nGrowth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.\nWith Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.\nImage source: Getty Images.\nMerck\nValue investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock Merck (NYSE:MRK) are now begging to be bought.\n\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of Pfizer's (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients. Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.\nBut here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.\nThe front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.\nThe other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.\nFollowing its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.\nImage source: Getty Images.\nVerizon\nFinally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth Verizon (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.\nThere look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.\nBut similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.\nDespite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.\nThe other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.\nVerizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.","news_type":1},"isVote":1,"tweetType":1,"viewCount":201,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606898447,"gmtCreate":1638851130355,"gmtModify":1638851131288,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TWTR\">$Twitter(TWTR)$</a>เธอสั่งให้รอฉันก็รออย่างมีจุดหมาย","listText":"<a href=\"https://laohu8.com/S/TWTR\">$Twitter(TWTR)$</a>เธอสั่งให้รอฉันก็รออย่างมีจุดหมาย","text":"$Twitter(TWTR)$เธอสั่งให้รอฉันก็รออย่างมีจุดหมาย","images":[{"img":"https://static.tigerbbs.com/6da83692b0f892c9884037c615ca74bd","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606898447","isVote":1,"tweetType":1,"viewCount":145,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":606149768,"gmtCreate":1638846484378,"gmtModify":1638846486449,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍 ","listText":"👍 ","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606149768","repostId":"1186134052","repostType":4,"repost":{"id":"1186134052","pubTimestamp":1638843447,"share":"https://www.laohu8.com/m/news/1186134052?lang=&edition=full","pubTime":"2021-12-07 10:17","market":"us","language":"en","title":"RIVN Price Prediction: Why One Analyst Sees Rivian Stock Hitting $147","url":"https://stock-news.laohu8.com/highlight/detail?id=1186134052","media":"InvestorPlace","summary":"Today, investors of a certain electric vehicle (EV) maker are breathing a big sigh of relief. Indeed","content":"<p>Today, investors of a certain electric vehicle (EV) maker are breathing a big sigh of relief. Indeed, last week <b>Rivian Automative</b>(NASDAQ:<b><u>RIVN</u></b>) had a rough go. RIVN stock dropped by 12% over the course of the week.</p>\n<p>However, things are turning around today as <b>Morgan Stanley</b>(NYSE:<b><u>MS</u></b>)initiated coverage on RIVN stock with an overweight rating and a $147 price target. This price target represents an upside of 34% from current prices. In response, shares of RIVN stock are trading higher by 4%.</p>\n<p>Let’s take a look at the details of this new price prediction.</p>\n<p>RIVN Price Prediction: Is Rivian “The One” to Challenge Tesla?</p>\n<p>Morgan Stanley analyst Adam Jonas led the initiation coverage on Rivian. However, it wasn’t necessarily the price target that attracted the most attention. It was Jonas’ comment on Rivian competitor <b>Tesla</b>(NASDAQ:<b><u>TSLA</u></b>) that surprised many investors:</p>\n<blockquote>\n “Rivian’s compelling product, strong management, and deterministic access to capital are underpinned by a strategic relationship with AMZN to decarbonize the final mile. We see it as ‘the one’ that can challenge Tesla.”\n</blockquote>\n<p>A direct comparison between the two EV makers seems far off for now. However, Rivian may have the one-up on Tesla in terms of delivery vans. Jonas calls Rivian’s delivery vans “the most capable/desirable product in the market for $80k.” While Tesla has yet to enter the delivery van market, its strength lies in selling EVs directly to consumers.</p>\n<p>On that note, Rivian launched its highly anticipated R1T pickup truck this year after supply chain delays. Deliveries for the pickup truck have started, although many customers who preordered are reporting that they won’t receive their order until 2022. Prices start at $67,5o0 for the base R1T model.</p>\n<p>According to <i>Tipranks</i>, Adam Jonas has a 57% success rate and an average return of 14.5% during a one-year period. Jonas is a highly regarded analyst and ranks at 465 out of the 7,727 total analysts that<i>Tipranks</i>tracks.</p>\n<p>The Bottom Line on Rivian</p>\n<p>Rivian remains a speculative investment with high future expectations. While Rivian has reported $0 in revenue for the trailing-12-month (TTM) period, the EV maker boasts an impressive ally in <b>Amazon</b>(NASDAQ:<b><u>AMZN</u></b>). Amazon is Rivian’s largest customer and owns roughly 20% of the company. Furthermore, the e-commerce giant has a massive pre-order for 100,000 delivery vans that is set to be completed by 2025. Analyst Adam Jonas believes the pre-order figure will increase to 300,000.</p>\n<p>As of now, valuation, scalability and execution by management remain the biggest concerns. Before making an investment, investors need to sit down and rationalize whether Rivian can make enough deliveries in the future to support its current sky-high market capitalization of $90 billion.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RIVN Price Prediction: Why One Analyst Sees Rivian Stock Hitting $147</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRIVN Price Prediction: Why One Analyst Sees Rivian Stock Hitting $147\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 10:17 GMT+8 <a href=https://investorplace.com/2021/12/rivn-price-prediction-why-one-analyst-sees-rivian-stock-hitting-147/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Today, investors of a certain electric vehicle (EV) maker are breathing a big sigh of relief. Indeed, last week Rivian Automative(NASDAQ:RIVN) had a rough go. RIVN stock dropped by 12% over the course...</p>\n\n<a href=\"https://investorplace.com/2021/12/rivn-price-prediction-why-one-analyst-sees-rivian-stock-hitting-147/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc."},"source_url":"https://investorplace.com/2021/12/rivn-price-prediction-why-one-analyst-sees-rivian-stock-hitting-147/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186134052","content_text":"Today, investors of a certain electric vehicle (EV) maker are breathing a big sigh of relief. Indeed, last week Rivian Automative(NASDAQ:RIVN) had a rough go. RIVN stock dropped by 12% over the course of the week.\nHowever, things are turning around today as Morgan Stanley(NYSE:MS)initiated coverage on RIVN stock with an overweight rating and a $147 price target. This price target represents an upside of 34% from current prices. In response, shares of RIVN stock are trading higher by 4%.\nLet’s take a look at the details of this new price prediction.\nRIVN Price Prediction: Is Rivian “The One” to Challenge Tesla?\nMorgan Stanley analyst Adam Jonas led the initiation coverage on Rivian. However, it wasn’t necessarily the price target that attracted the most attention. It was Jonas’ comment on Rivian competitor Tesla(NASDAQ:TSLA) that surprised many investors:\n\n “Rivian’s compelling product, strong management, and deterministic access to capital are underpinned by a strategic relationship with AMZN to decarbonize the final mile. We see it as ‘the one’ that can challenge Tesla.”\n\nA direct comparison between the two EV makers seems far off for now. However, Rivian may have the one-up on Tesla in terms of delivery vans. Jonas calls Rivian’s delivery vans “the most capable/desirable product in the market for $80k.” While Tesla has yet to enter the delivery van market, its strength lies in selling EVs directly to consumers.\nOn that note, Rivian launched its highly anticipated R1T pickup truck this year after supply chain delays. Deliveries for the pickup truck have started, although many customers who preordered are reporting that they won’t receive their order until 2022. Prices start at $67,5o0 for the base R1T model.\nAccording to Tipranks, Adam Jonas has a 57% success rate and an average return of 14.5% during a one-year period. Jonas is a highly regarded analyst and ranks at 465 out of the 7,727 total analysts thatTiprankstracks.\nThe Bottom Line on Rivian\nRivian remains a speculative investment with high future expectations. While Rivian has reported $0 in revenue for the trailing-12-month (TTM) period, the EV maker boasts an impressive ally in Amazon(NASDAQ:AMZN). Amazon is Rivian’s largest customer and owns roughly 20% of the company. Furthermore, the e-commerce giant has a massive pre-order for 100,000 delivery vans that is set to be completed by 2025. Analyst Adam Jonas believes the pre-order figure will increase to 300,000.\nAs of now, valuation, scalability and execution by management remain the biggest concerns. Before making an investment, investors need to sit down and rationalize whether Rivian can make enough deliveries in the future to support its current sky-high market capitalization of $90 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":309,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608710604,"gmtCreate":1638788963960,"gmtModify":1638788968330,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Downstairs ","listText":"Downstairs ","text":"Downstairs","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608710604","repostId":"2138143109","repostType":4,"repost":{"id":"2138143109","pubTimestamp":1622042760,"share":"https://www.laohu8.com/m/news/2138143109?lang=&edition=full","pubTime":"2021-05-26 23:26","market":"us","language":"en","title":"Why American Eagle Outfitters Is Jumping 5.5% Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2138143109","media":"Motley Fool","summary":"The apparel retailer has strong tailwinds behind it.","content":"<h2>What happened</h2><p>Shares of <b>American Eagle Outfitters</b> (NYSE:AEO) were up 5.5% in morning trading Wednesday ahead of the apparel retailer reporting first-quarter earnings after the market closes.</p><h2>So what</h2><p>Many retailers are posting strong quarterly financials as they go up against comparatively weak comparable sales from the year-ago period, which was partially marred by the coronavirus pandemic outbreak. Both <b>Abercrombie & Fitch</b> and <b><a href=\"https://laohu8.com/S/URBN\">Urban Outfitters</a></b> just handily beat estimates.</p><p>Investors might view American Eagle as prepared to beat analyst expectations on the strength of its Aerie loungewear brand, which has been a strong performer throughout. Especially as working from home became an imperative for many -- and still is -- comfortable clothes that met various fashion needs became de rigueur for consumers.</p><p>Analysts expect Aerie to become a $2 billion to $3 billion brand, and it already accounts for 40% American Eagle's sales.</p><h2>Now what</h2><p>Wall Street expects American Eagle to post revenue of $1.02 billion, up 85% over the year-ago quarter, generating earnings of $0.47 per share compared to an adjusted loss of $0.84 per share (analyst estimates typically don't include <a href=\"https://laohu8.com/S/AONE\">one</a>-time items that companies end up adjusting their results for).</p><p>It already looks as though American Eagle is expected to post robust results, so the market will end up reacting tomorrow to just how much the retailer beats (or misses) those forecasts.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why American Eagle Outfitters Is Jumping 5.5% Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy American Eagle Outfitters Is Jumping 5.5% Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-26 23:26 GMT+8 <a href=https://www.fool.com/investing/2021/05/26/why-american-eagle-outfitters-is-jumping-55-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedShares of American Eagle Outfitters (NYSE:AEO) were up 5.5% in morning trading Wednesday ahead of the apparel retailer reporting first-quarter earnings after the market closes.So whatMany...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/26/why-american-eagle-outfitters-is-jumping-55-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AFG":"美国金融集团有限公司","AMSWA":"美国软件","AEO":"美鹰服饰","EGBN":"伊格尔合众银行"},"source_url":"https://www.fool.com/investing/2021/05/26/why-american-eagle-outfitters-is-jumping-55-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138143109","content_text":"What happenedShares of American Eagle Outfitters (NYSE:AEO) were up 5.5% in morning trading Wednesday ahead of the apparel retailer reporting first-quarter earnings after the market closes.So whatMany retailers are posting strong quarterly financials as they go up against comparatively weak comparable sales from the year-ago period, which was partially marred by the coronavirus pandemic outbreak. Both Abercrombie & Fitch and Urban Outfitters just handily beat estimates.Investors might view American Eagle as prepared to beat analyst expectations on the strength of its Aerie loungewear brand, which has been a strong performer throughout. Especially as working from home became an imperative for many -- and still is -- comfortable clothes that met various fashion needs became de rigueur for consumers.Analysts expect Aerie to become a $2 billion to $3 billion brand, and it already accounts for 40% American Eagle's sales.Now whatWall Street expects American Eagle to post revenue of $1.02 billion, up 85% over the year-ago quarter, generating earnings of $0.47 per share compared to an adjusted loss of $0.84 per share (analyst estimates typically don't include one-time items that companies end up adjusting their results for).It already looks as though American Eagle is expected to post robust results, so the market will end up reacting tomorrow to just how much the retailer beats (or misses) those forecasts.","news_type":1},"isVote":1,"tweetType":1,"viewCount":340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601790846,"gmtCreate":1638556737583,"gmtModify":1638556738033,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"😢","listText":"😢","text":"😢","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/601790846","repostId":"1195177271","repostType":4,"repost":{"id":"1195177271","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638542957,"share":"https://www.laohu8.com/m/news/1195177271?lang=&edition=full","pubTime":"2021-12-03 22:49","market":"us","language":"en","title":"Hot chinese concept stocks dipped in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1195177271","media":"Tiger Newspress","summary":"Hot chinese concept stocks dipped in morning trading.Alibaba,JD.com,Pinduoduo,Baidu,NetEase,Bilibili,Nio,Xpeng Motors,Li Auto,DiDi Global and KE Holdings fell between 4% and 10%.","content":"<p>Hot chinese concept stocks dipped in morning trading.Alibaba,JD.com,Pinduoduo,Baidu,NetEase,Bilibili,Nio,Xpeng Motors,Li Auto,DiDi Global and KE Holdings fell between 4% and 10%.</p>\n<p><img src=\"https://static.tigerbbs.com/364eb167dd032a1d1046b0f329d247db\" tg-width=\"402\" tg-height=\"666\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hot chinese concept stocks dipped in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHot chinese concept stocks dipped in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-03 22:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hot chinese concept stocks dipped in morning trading.Alibaba,JD.com,Pinduoduo,Baidu,NetEase,Bilibili,Nio,Xpeng Motors,Li Auto,DiDi Global and KE Holdings fell between 4% and 10%.</p>\n<p><img src=\"https://static.tigerbbs.com/364eb167dd032a1d1046b0f329d247db\" tg-width=\"402\" tg-height=\"666\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DIDI":"滴滴(已退市)","BABA":"阿里巴巴","JD":"京东","NIO":"蔚来","BILI":"哔哩哔哩","XPEV":"小鹏汽车","BIDU":"百度","LI":"理想汽车","PDD":"拼多多","BEKE":"贝壳","NTES":"网易"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195177271","content_text":"Hot chinese concept stocks dipped in morning trading.Alibaba,JD.com,Pinduoduo,Baidu,NetEase,Bilibili,Nio,Xpeng Motors,Li Auto,DiDi Global and KE Holdings fell between 4% and 10%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":154,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601210045,"gmtCreate":1638533688808,"gmtModify":1638533703139,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good ","listText":"Good ","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/601210045","repostId":"1144924535","repostType":4,"repost":{"id":"1144924535","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据,旨在帮助投资者理解世界,做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638533072,"share":"https://www.laohu8.com/m/news/1144924535?lang=&edition=full","pubTime":"2021-12-03 20:04","market":"us","language":"en","title":"Moderna stock jumped more than 5% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1144924535","media":"老虎资讯综合","summary":"Moderna stock jumped more than 5% in premarket trading because Moderna led with antibody response in","content":"<p>Moderna stock jumped more than 5% in premarket trading because Moderna led with antibody response in COVID-19 booster trial in U.K..</p>\n<p><img src=\"https://static.tigerbbs.com/7b43bf58e1f0e28dcfc0f4c263ef6736\" tg-width=\"853\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p>According to a peer-reviewed study published in <i>The Lancet</i> on Thursday, Moderna COVID-19 vaccine has shown the strongest antibody effect in a trial that evaluated the different combinations of COVID-19 vaccines as boosters.</p>\n<p>The Phase 2 \"COV-Boost\" study conducted across 18 different U.K. locations involved nearly 2,900 individuals aged over 30 years. Half in the study had received two doses of Oxford-AstraZeneca vaccine, and the rest had received the Pfizer/BioNTec vaccine.</p>\n<p>The trial was designed to evaluate the safety and efficacy of seven booster vaccines developed by AstraZeneca, Pfizer/ BioNTech, Novavax, Johnson & Johnson, Moderna, Valneva and Curevac.</p>\n<p>While all seven vaccines except Valneva’s (VALN) boosted immunity in those who had received initial doses of Pfizer/ BioNTech, all seven had upped the immunity level when given 10 – 12 weeks after the initial regimen of the AstraZeneca vaccine.</p>\n<p>Notably, Moderna COVID-19 shot had generated the strongest booster effect leading to an over 32-fold rise in antibody level in the AstraZeneca group and over 11-fold increase in the Pfizer/ BioNTech group, <i>The Guardian</i> reported.</p>\n<p>In addition,Britain said on Wednesday it had agreed deals to buy 114 million more Pfizer/BioNTech and Moderna COVID-19 vaccine shots, saying it had sped up signing the new contracts in light of the emergence of the new Omicron variant.</p>\n<p>The deal involves an additional 60 million Moderna shots and 54 million Pfizer doses for next year and 2023, and will also include access to any modified vaccinations if they are needed to combat the Omicron strain or any other variant, the British health ministry said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock jumped more than 5% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock jumped more than 5% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-12-03 20:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna stock jumped more than 5% in premarket trading because Moderna led with antibody response in COVID-19 booster trial in U.K..</p>\n<p><img src=\"https://static.tigerbbs.com/7b43bf58e1f0e28dcfc0f4c263ef6736\" tg-width=\"853\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p>According to a peer-reviewed study published in <i>The Lancet</i> on Thursday, Moderna COVID-19 vaccine has shown the strongest antibody effect in a trial that evaluated the different combinations of COVID-19 vaccines as boosters.</p>\n<p>The Phase 2 \"COV-Boost\" study conducted across 18 different U.K. locations involved nearly 2,900 individuals aged over 30 years. Half in the study had received two doses of Oxford-AstraZeneca vaccine, and the rest had received the Pfizer/BioNTec vaccine.</p>\n<p>The trial was designed to evaluate the safety and efficacy of seven booster vaccines developed by AstraZeneca, Pfizer/ BioNTech, Novavax, Johnson & Johnson, Moderna, Valneva and Curevac.</p>\n<p>While all seven vaccines except Valneva’s (VALN) boosted immunity in those who had received initial doses of Pfizer/ BioNTech, all seven had upped the immunity level when given 10 – 12 weeks after the initial regimen of the AstraZeneca vaccine.</p>\n<p>Notably, Moderna COVID-19 shot had generated the strongest booster effect leading to an over 32-fold rise in antibody level in the AstraZeneca group and over 11-fold increase in the Pfizer/ BioNTech group, <i>The Guardian</i> reported.</p>\n<p>In addition,Britain said on Wednesday it had agreed deals to buy 114 million more Pfizer/BioNTech and Moderna COVID-19 vaccine shots, saying it had sped up signing the new contracts in light of the emergence of the new Omicron variant.</p>\n<p>The deal involves an additional 60 million Moderna shots and 54 million Pfizer doses for next year and 2023, and will also include access to any modified vaccinations if they are needed to combat the Omicron strain or any other variant, the British health ministry said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144924535","content_text":"Moderna stock jumped more than 5% in premarket trading because Moderna led with antibody response in COVID-19 booster trial in U.K..\n\nAccording to a peer-reviewed study published in The Lancet on Thursday, Moderna COVID-19 vaccine has shown the strongest antibody effect in a trial that evaluated the different combinations of COVID-19 vaccines as boosters.\nThe Phase 2 \"COV-Boost\" study conducted across 18 different U.K. locations involved nearly 2,900 individuals aged over 30 years. Half in the study had received two doses of Oxford-AstraZeneca vaccine, and the rest had received the Pfizer/BioNTec vaccine.\nThe trial was designed to evaluate the safety and efficacy of seven booster vaccines developed by AstraZeneca, Pfizer/ BioNTech, Novavax, Johnson & Johnson, Moderna, Valneva and Curevac.\nWhile all seven vaccines except Valneva’s (VALN) boosted immunity in those who had received initial doses of Pfizer/ BioNTech, all seven had upped the immunity level when given 10 – 12 weeks after the initial regimen of the AstraZeneca vaccine.\nNotably, Moderna COVID-19 shot had generated the strongest booster effect leading to an over 32-fold rise in antibody level in the AstraZeneca group and over 11-fold increase in the Pfizer/ BioNTech group, The Guardian reported.\nIn addition,Britain said on Wednesday it had agreed deals to buy 114 million more Pfizer/BioNTech and Moderna COVID-19 vaccine shots, saying it had sped up signing the new contracts in light of the emergence of the new Omicron variant.\nThe deal involves an additional 60 million Moderna shots and 54 million Pfizer doses for next year and 2023, and will also include access to any modified vaccinations if they are needed to combat the Omicron strain or any other variant, the British health ministry said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":323,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603553063,"gmtCreate":1638431137685,"gmtModify":1638431139320,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603553063","repostId":"1197973971","repostType":4,"repost":{"id":"1197973971","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638429281,"share":"https://www.laohu8.com/m/news/1197973971?lang=&edition=full","pubTime":"2021-12-02 15:14","market":"us","language":"en","title":"Glaxo says its vaccine retains activity against key Omicron mutations","url":"https://stock-news.laohu8.com/highlight/detail?id=1197973971","media":"Tiger Newspress","summary":"GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced an update to bioRxiv, a preprint ser","content":"<p>GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced an update to bioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations[1] of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab. These data were generated through pseudo-virus testing of specific individual mutations found in Omicron. To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO). The companies are now completing in vitro pseudo-virus testing to confirm the neutralising activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021.</p>\n<p><b>George Scangos, PhD, Chief Executive Officer of Vir, said:</b>“Sotrovimab was deliberately designed with a mutating virus in mind. By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to address both the current SARS-CoV-2 virus and future variants that we expected would be inevitable. This hypothesis has borne out again and again – with its ongoing ability to maintain activity against all tested variants of concern and interest to date, including key mutations found in Omicron, as demonstrated by preclinical data. We have every expectation that this positive trend will continue and are working rapidly to confirm its activity against the full combination sequence of Omicron.”</p>\n<p><b>Dr Hal Barron, Chief Scientific Officer and President R&D, GSK, said:</b>“Since the beginning of the pandemic, we have been working with Vir to combine our scientific expertise and technologies to deliver an enduring treatment option for patients with COVID-19. Though very early, these pre-clinical data support our long-held view on the potential for sotrovimab to maintain its activity as the virus continues to mutate. We are pleased that this treatment option is available to patients in the US and many other countries, and are working to expand access worldwide.”</p>\n<p><b>About sotrovimab</b></p>\n<p>Sotrovimab is an investigational SARS-CoV-2 neutralising monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. Sotrovimab, which incorporates Xencor’s Xtend™ technology, has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.</p>\n<p>Updated in vitro data, published in bioRxiv, demonstrate that sotrovimab retains activity against all current tested variants of concern and interest of the SARS-CoV-2 virus as defined by WHO, plus others, including but not limited to Delta (B.1.617.2), Delta Plus (AY.1 or AY.2), Mu (B.1.621) and key mutations of Omicron (B.1.1.529).</p>\n<p><b>About the sotrovimab clinical development programme</b></p>\n<ul>\n <li>COMET-ICE: a Phase III, multi-centre, double-blind, placebo-controlled trial investigated an intravenous (IV) infusion of sotrovimab in adults with mild-to-moderate COVID-19 at high risk of progression to severe disease, who are not hospitalised and not requiring oxygen. The final COMET-ICE trial results in the full trial population of 1,057 participants demonstrated a 79% reduction (adjusted relative risk reduction) (p<0.001) in hospitalisation for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. Interim data were published in<i>The New England Journal of Medicine</i>on 27 October 2021 and final data were pre-published on 8 November 2021 on<i>medRxiv</i>.</li>\n <li>COMET-TAIL: a Phase III, randomised, multi-centre, open-label, non-inferiority trial of intramuscular (IM) versus IV administration of sotrovimab for the early treatment of mild-to-moderate COVID-19 in high-risk non-hospitalised adult and paediatric patients (12 years of age and older). The trial’s primary endpoint was met, and headline data demonstrated that intramuscularly administered sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations. The companies plan to submit the complete COMET-TAIL data set to a peer-reviewed journal for publication in the first quarter of 2022.</li>\n <li>COMET-PEAK: a Phase II, randomised, multi-centre, parallel-group trial evaluating IV and IM administration of sotrovimab in outpatients with mild-to-moderate COVID-19. Data available to date from open-label Part B of the trial (500mg IV vs. 500mg IM) demonstrated equivalence on the virological response between the IM and IV arms. The companies plan to submit the complete COMET-PEAK data set to a peer-reviewed journal for publication in due course.</li>\n <li>GSK and Vir are also partnering to investigate the use of sotrovimab in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection. GSK and Vir are supporting investigator-sponsored studies and fostering scientific collaborations with experienced investigators and networks involved in the continuum of care of immunocompromised patients, to understand the role sotrovimab for prophylaxis could play in this population. Discussions with regulatory authorities regarding the prophylaxis programme will take place in due course.</li>\n</ul>\n<p><b>About global access to sotrovimab</b></p>\n<ul>\n <li>Sotrovimab is authorised for emergency use in the United States. Xevudy (sotrovimab) received apositive scientific opinionunder Article 5(3) of Regulation 726/2004 from the Committee for Human Medicinal Products (CHMP) in the EU, has been granted a provisional marketing authorisation in Australia, and conditional marketing authorisation in Saudi Arabia. In Japan, it has been approved via the Special Approval for Emergency Pathway. Temporary authorisations for sotrovimab have been granted in a dozen countries.</li>\n <li>GSK and Vir also recently submitted the Marketing Authorisation Application (MAA) to the European Medicines Agency for Xevudy (sotrovimab) for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at risk of progressing to severe</li>\n <li>COVID-19.</li>\n <li>Sotrovimab is supplied in several countries worldwide, including through national agreements in the United States, United Kingdom, Japan, Australia, Canada, Singapore, Switzerland and United Arab Emirates. We have also signed a Joint Procurement Agreement with the European Commission to supply doses of sotrovimab. Additional agreements are yet to be announced due to confidentiality or regulatory requirements.</li>\n</ul>\n<p><b>Sotrovimab in the United States</b></p>\n<p>The following is a summary of information for sotrovimab. Healthcare providers in the U.S. should review the Fact Sheets for information about the authorised use of sotrovimab and mandatory requirements of the EUA. Please see theFood and Drug Administration (FDA) Letter of Authorization, fullFact Sheet for Healthcare Providers, and fullFact Sheet for Patients, Parents, and Caregivers.</p>\n<p>Sotrovimab has been authorized by the U.S. FDA for the emergency use described below. Sotrovimab is not FDA-approved for this use.</p>\n<p>Sotrovimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of sotrovimab under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.</p>\n<p><b>Authorized Use</b></p>\n<p>The U.S. FDA has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.</p>\n<p><b>Limitations of Authorized Use</b></p>\n<p>Sotrovimab is not authorized for use in patients:</p>\n<ul>\n <li>who are hospitalized due to COVID-19, OR</li>\n <li>who require oxygen therapy due to COVID-19, OR</li>\n <li>who require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity)</li>\n</ul>\n<p>Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID 19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID 19 requiring high flow oxygen or mechanical ventilation.</p>\n<p><b>Important Safety Information</b></p>\n<p><b>CONTRAINDICATIONS</b></p>\n<p>Sotrovimab is contraindicated in patients who have a history of anaphylaxis to sotrovimab or to any of the excipients in the formulation.</p>\n<p><b>WARNINGS AND PRECAUTIONS</b></p>\n<p>There are limited clinical data available for sotrovimab. Serious and unexpected adverse events may occur that have not been previously reported with sotrovimab use.</p>\n<p><b>Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions</b></p>\n<p>Serious hypersensitivity reactions, including anaphylaxis, have been observed with administration of sotrovimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.</p>\n<p>Infusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of sotrovimab. These reactions may be severe or life threatening.</p>\n<p>Signs and symptoms of infusion-related reactions may include: fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions (eg, pre-syncope, syncope), dizziness and diaphoresis.</p>\n<p>Consider slowing or stopping the infusion and administer appropriate medications and/or supportive care if an infusion-related reaction occurs.</p>\n<p>Hypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization.</p>\n<p><b>Clinical Worsening After SARS-CoV-2 Monoclonal Antibody Administration</b></p>\n<p>Clinical worsening of COVID‑19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (eg, atrial fibrillation, tachycardia, bradycardia), fatigue, and altered mental status. Some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID‑19.</p>\n<p><b>Limitations of Benefit and Potential for Risk in Patients with Severe COVID‑19</b></p>\n<p>Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation. Therefore, sotrovimab is not authorized for use in patients: who are hospitalized due to COVID‑19, OR who require oxygen therapy due to COVID‑19, OR who require an increase in baseline oxygen flow rate due to COVID‑19 in those on chronic oxygen therapy due to underlying non‑COVID‑19 related comorbidity.</p>\n<p><b>ADVERSE EVENTS</b></p>\n<p>Hypersensitivity adverse reactions have been observed in 2% of patients treated with sotrovimab and 1% with placebo in COMET-ICE.</p>\n<p>The most common treatment-emergent adverse events observed in the sotrovimab treatment group in COMET-ICE were rash (1%) and diarrhea (2%), all of which were Grade 1 (mild) or Grade 2 (moderate). No other treatment-emergent adverse events were reported at a higher rate with sotrovimab compared to placebo.</p>\n<p><b>USE IN SPECIFIC POPULATIONS</b></p>\n<p><b>Pregnancy</b></p>\n<p>There are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome. Sotrovimab should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus.</p>\n<p><b>Lactation</b></p>\n<p>There are no available data on the presence of sotrovimab in human milk, the effects on the breastfed infant, or the effects on milk production. Individuals with COVID-19 who are breastfeeding should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.</p>\n<p><b>About the GSK and Vir collaboration</b></p>\n<p>In April 2020, GSK and Vir entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.</p>\n<p><b>GSK commitment to tackling COVID-19</b></p>\n<p>GSK’s response to COVID-19 has been one of the broadest in the industry, with potential treatments in addition to our vaccine candidates in development with partner organisations.</p>\n<p>GSK is collaborating with several organisations on COVID-19 vaccines by providing access to our adjuvant technology. We are working with Sanofi S.A., Medicago Inc. and SK bioscience Co., Ltd. to develop adjuvanted, protein-based vaccine candidates, and all are now in Phase III clinical trials. The use of an adjuvant can be of particular importance in a pandemic since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and contributing to protecting more people in need.</p>\n<p>GSK is also working with mRNA specialist, CureVac N.V., to jointly develop next-generation, optimised mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine.</p>\n<p>GSK is also exploring treatments for COVID-19 patients, collaborating with Vir Biotechnology to investigate monoclonal antibodies that could be used as therapeutic or preventive options for COVID-19.</p>\n<p><b>Vir’s commitment to COVID-19</b></p>\n<p>Vir was founded with the mission of addressing the world’s most serious infectious diseases. In 2020, Vir responded rapidly to the COVID-19 pandemic by leveraging our unique scientific insights and industry-leading antibody platform to explore multiple monoclonal antibodies as potential therapeutic or preventive options for COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir advanced into the clinic. It was carefully selected for its demonstrated promise in preclinical research, including an anticipated high barrier to resistance and potential ability to both block the virus from entering healthy cells and clear infected cells. Vir is continuing to pursue novel therapeutic and prophylactic solutions to combat SARS-CoV-2 and future coronavirus pandemics, both independently and in collaboration with its partners.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo says its vaccine retains activity against key Omicron mutations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo says its vaccine retains activity against key Omicron mutations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 15:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced an update to bioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations[1] of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab. These data were generated through pseudo-virus testing of specific individual mutations found in Omicron. To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO). The companies are now completing in vitro pseudo-virus testing to confirm the neutralising activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021.</p>\n<p><b>George Scangos, PhD, Chief Executive Officer of Vir, said:</b>“Sotrovimab was deliberately designed with a mutating virus in mind. By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to address both the current SARS-CoV-2 virus and future variants that we expected would be inevitable. This hypothesis has borne out again and again – with its ongoing ability to maintain activity against all tested variants of concern and interest to date, including key mutations found in Omicron, as demonstrated by preclinical data. We have every expectation that this positive trend will continue and are working rapidly to confirm its activity against the full combination sequence of Omicron.”</p>\n<p><b>Dr Hal Barron, Chief Scientific Officer and President R&D, GSK, said:</b>“Since the beginning of the pandemic, we have been working with Vir to combine our scientific expertise and technologies to deliver an enduring treatment option for patients with COVID-19. Though very early, these pre-clinical data support our long-held view on the potential for sotrovimab to maintain its activity as the virus continues to mutate. We are pleased that this treatment option is available to patients in the US and many other countries, and are working to expand access worldwide.”</p>\n<p><b>About sotrovimab</b></p>\n<p>Sotrovimab is an investigational SARS-CoV-2 neutralising monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. Sotrovimab, which incorporates Xencor’s Xtend™ technology, has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.</p>\n<p>Updated in vitro data, published in bioRxiv, demonstrate that sotrovimab retains activity against all current tested variants of concern and interest of the SARS-CoV-2 virus as defined by WHO, plus others, including but not limited to Delta (B.1.617.2), Delta Plus (AY.1 or AY.2), Mu (B.1.621) and key mutations of Omicron (B.1.1.529).</p>\n<p><b>About the sotrovimab clinical development programme</b></p>\n<ul>\n <li>COMET-ICE: a Phase III, multi-centre, double-blind, placebo-controlled trial investigated an intravenous (IV) infusion of sotrovimab in adults with mild-to-moderate COVID-19 at high risk of progression to severe disease, who are not hospitalised and not requiring oxygen. The final COMET-ICE trial results in the full trial population of 1,057 participants demonstrated a 79% reduction (adjusted relative risk reduction) (p<0.001) in hospitalisation for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. Interim data were published in<i>The New England Journal of Medicine</i>on 27 October 2021 and final data were pre-published on 8 November 2021 on<i>medRxiv</i>.</li>\n <li>COMET-TAIL: a Phase III, randomised, multi-centre, open-label, non-inferiority trial of intramuscular (IM) versus IV administration of sotrovimab for the early treatment of mild-to-moderate COVID-19 in high-risk non-hospitalised adult and paediatric patients (12 years of age and older). The trial’s primary endpoint was met, and headline data demonstrated that intramuscularly administered sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations. The companies plan to submit the complete COMET-TAIL data set to a peer-reviewed journal for publication in the first quarter of 2022.</li>\n <li>COMET-PEAK: a Phase II, randomised, multi-centre, parallel-group trial evaluating IV and IM administration of sotrovimab in outpatients with mild-to-moderate COVID-19. Data available to date from open-label Part B of the trial (500mg IV vs. 500mg IM) demonstrated equivalence on the virological response between the IM and IV arms. The companies plan to submit the complete COMET-PEAK data set to a peer-reviewed journal for publication in due course.</li>\n <li>GSK and Vir are also partnering to investigate the use of sotrovimab in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection. GSK and Vir are supporting investigator-sponsored studies and fostering scientific collaborations with experienced investigators and networks involved in the continuum of care of immunocompromised patients, to understand the role sotrovimab for prophylaxis could play in this population. Discussions with regulatory authorities regarding the prophylaxis programme will take place in due course.</li>\n</ul>\n<p><b>About global access to sotrovimab</b></p>\n<ul>\n <li>Sotrovimab is authorised for emergency use in the United States. Xevudy (sotrovimab) received apositive scientific opinionunder Article 5(3) of Regulation 726/2004 from the Committee for Human Medicinal Products (CHMP) in the EU, has been granted a provisional marketing authorisation in Australia, and conditional marketing authorisation in Saudi Arabia. In Japan, it has been approved via the Special Approval for Emergency Pathway. Temporary authorisations for sotrovimab have been granted in a dozen countries.</li>\n <li>GSK and Vir also recently submitted the Marketing Authorisation Application (MAA) to the European Medicines Agency for Xevudy (sotrovimab) for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at risk of progressing to severe</li>\n <li>COVID-19.</li>\n <li>Sotrovimab is supplied in several countries worldwide, including through national agreements in the United States, United Kingdom, Japan, Australia, Canada, Singapore, Switzerland and United Arab Emirates. We have also signed a Joint Procurement Agreement with the European Commission to supply doses of sotrovimab. Additional agreements are yet to be announced due to confidentiality or regulatory requirements.</li>\n</ul>\n<p><b>Sotrovimab in the United States</b></p>\n<p>The following is a summary of information for sotrovimab. Healthcare providers in the U.S. should review the Fact Sheets for information about the authorised use of sotrovimab and mandatory requirements of the EUA. Please see theFood and Drug Administration (FDA) Letter of Authorization, fullFact Sheet for Healthcare Providers, and fullFact Sheet for Patients, Parents, and Caregivers.</p>\n<p>Sotrovimab has been authorized by the U.S. FDA for the emergency use described below. Sotrovimab is not FDA-approved for this use.</p>\n<p>Sotrovimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of sotrovimab under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.</p>\n<p><b>Authorized Use</b></p>\n<p>The U.S. FDA has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.</p>\n<p><b>Limitations of Authorized Use</b></p>\n<p>Sotrovimab is not authorized for use in patients:</p>\n<ul>\n <li>who are hospitalized due to COVID-19, OR</li>\n <li>who require oxygen therapy due to COVID-19, OR</li>\n <li>who require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity)</li>\n</ul>\n<p>Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID 19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID 19 requiring high flow oxygen or mechanical ventilation.</p>\n<p><b>Important Safety Information</b></p>\n<p><b>CONTRAINDICATIONS</b></p>\n<p>Sotrovimab is contraindicated in patients who have a history of anaphylaxis to sotrovimab or to any of the excipients in the formulation.</p>\n<p><b>WARNINGS AND PRECAUTIONS</b></p>\n<p>There are limited clinical data available for sotrovimab. Serious and unexpected adverse events may occur that have not been previously reported with sotrovimab use.</p>\n<p><b>Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions</b></p>\n<p>Serious hypersensitivity reactions, including anaphylaxis, have been observed with administration of sotrovimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.</p>\n<p>Infusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of sotrovimab. These reactions may be severe or life threatening.</p>\n<p>Signs and symptoms of infusion-related reactions may include: fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions (eg, pre-syncope, syncope), dizziness and diaphoresis.</p>\n<p>Consider slowing or stopping the infusion and administer appropriate medications and/or supportive care if an infusion-related reaction occurs.</p>\n<p>Hypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization.</p>\n<p><b>Clinical Worsening After SARS-CoV-2 Monoclonal Antibody Administration</b></p>\n<p>Clinical worsening of COVID‑19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (eg, atrial fibrillation, tachycardia, bradycardia), fatigue, and altered mental status. Some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID‑19.</p>\n<p><b>Limitations of Benefit and Potential for Risk in Patients with Severe COVID‑19</b></p>\n<p>Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation. Therefore, sotrovimab is not authorized for use in patients: who are hospitalized due to COVID‑19, OR who require oxygen therapy due to COVID‑19, OR who require an increase in baseline oxygen flow rate due to COVID‑19 in those on chronic oxygen therapy due to underlying non‑COVID‑19 related comorbidity.</p>\n<p><b>ADVERSE EVENTS</b></p>\n<p>Hypersensitivity adverse reactions have been observed in 2% of patients treated with sotrovimab and 1% with placebo in COMET-ICE.</p>\n<p>The most common treatment-emergent adverse events observed in the sotrovimab treatment group in COMET-ICE were rash (1%) and diarrhea (2%), all of which were Grade 1 (mild) or Grade 2 (moderate). No other treatment-emergent adverse events were reported at a higher rate with sotrovimab compared to placebo.</p>\n<p><b>USE IN SPECIFIC POPULATIONS</b></p>\n<p><b>Pregnancy</b></p>\n<p>There are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome. Sotrovimab should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus.</p>\n<p><b>Lactation</b></p>\n<p>There are no available data on the presence of sotrovimab in human milk, the effects on the breastfed infant, or the effects on milk production. Individuals with COVID-19 who are breastfeeding should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.</p>\n<p><b>About the GSK and Vir collaboration</b></p>\n<p>In April 2020, GSK and Vir entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.</p>\n<p><b>GSK commitment to tackling COVID-19</b></p>\n<p>GSK’s response to COVID-19 has been one of the broadest in the industry, with potential treatments in addition to our vaccine candidates in development with partner organisations.</p>\n<p>GSK is collaborating with several organisations on COVID-19 vaccines by providing access to our adjuvant technology. We are working with Sanofi S.A., Medicago Inc. and SK bioscience Co., Ltd. to develop adjuvanted, protein-based vaccine candidates, and all are now in Phase III clinical trials. The use of an adjuvant can be of particular importance in a pandemic since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and contributing to protecting more people in need.</p>\n<p>GSK is also working with mRNA specialist, CureVac N.V., to jointly develop next-generation, optimised mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine.</p>\n<p>GSK is also exploring treatments for COVID-19 patients, collaborating with Vir Biotechnology to investigate monoclonal antibodies that could be used as therapeutic or preventive options for COVID-19.</p>\n<p><b>Vir’s commitment to COVID-19</b></p>\n<p>Vir was founded with the mission of addressing the world’s most serious infectious diseases. In 2020, Vir responded rapidly to the COVID-19 pandemic by leveraging our unique scientific insights and industry-leading antibody platform to explore multiple monoclonal antibodies as potential therapeutic or preventive options for COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir advanced into the clinic. It was carefully selected for its demonstrated promise in preclinical research, including an anticipated high barrier to resistance and potential ability to both block the virus from entering healthy cells and clear infected cells. Vir is continuing to pursue novel therapeutic and prophylactic solutions to combat SARS-CoV-2 and future coronavirus pandemics, both independently and in collaboration with its partners.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197973971","content_text":"GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced an update to bioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations[1] of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab. These data were generated through pseudo-virus testing of specific individual mutations found in Omicron. To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO). The companies are now completing in vitro pseudo-virus testing to confirm the neutralising activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021.\nGeorge Scangos, PhD, Chief Executive Officer of Vir, said:“Sotrovimab was deliberately designed with a mutating virus in mind. By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to address both the current SARS-CoV-2 virus and future variants that we expected would be inevitable. This hypothesis has borne out again and again – with its ongoing ability to maintain activity against all tested variants of concern and interest to date, including key mutations found in Omicron, as demonstrated by preclinical data. We have every expectation that this positive trend will continue and are working rapidly to confirm its activity against the full combination sequence of Omicron.”\nDr Hal Barron, Chief Scientific Officer and President R&D, GSK, said:“Since the beginning of the pandemic, we have been working with Vir to combine our scientific expertise and technologies to deliver an enduring treatment option for patients with COVID-19. Though very early, these pre-clinical data support our long-held view on the potential for sotrovimab to maintain its activity as the virus continues to mutate. We are pleased that this treatment option is available to patients in the US and many other countries, and are working to expand access worldwide.”\nAbout sotrovimab\nSotrovimab is an investigational SARS-CoV-2 neutralising monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. Sotrovimab, which incorporates Xencor’s Xtend™ technology, has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.\nUpdated in vitro data, published in bioRxiv, demonstrate that sotrovimab retains activity against all current tested variants of concern and interest of the SARS-CoV-2 virus as defined by WHO, plus others, including but not limited to Delta (B.1.617.2), Delta Plus (AY.1 or AY.2), Mu (B.1.621) and key mutations of Omicron (B.1.1.529).\nAbout the sotrovimab clinical development programme\n\nCOMET-ICE: a Phase III, multi-centre, double-blind, placebo-controlled trial investigated an intravenous (IV) infusion of sotrovimab in adults with mild-to-moderate COVID-19 at high risk of progression to severe disease, who are not hospitalised and not requiring oxygen. The final COMET-ICE trial results in the full trial population of 1,057 participants demonstrated a 79% reduction (adjusted relative risk reduction) (p<0.001) in hospitalisation for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. Interim data were published inThe New England Journal of Medicineon 27 October 2021 and final data were pre-published on 8 November 2021 onmedRxiv.\nCOMET-TAIL: a Phase III, randomised, multi-centre, open-label, non-inferiority trial of intramuscular (IM) versus IV administration of sotrovimab for the early treatment of mild-to-moderate COVID-19 in high-risk non-hospitalised adult and paediatric patients (12 years of age and older). The trial’s primary endpoint was met, and headline data demonstrated that intramuscularly administered sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations. The companies plan to submit the complete COMET-TAIL data set to a peer-reviewed journal for publication in the first quarter of 2022.\nCOMET-PEAK: a Phase II, randomised, multi-centre, parallel-group trial evaluating IV and IM administration of sotrovimab in outpatients with mild-to-moderate COVID-19. Data available to date from open-label Part B of the trial (500mg IV vs. 500mg IM) demonstrated equivalence on the virological response between the IM and IV arms. The companies plan to submit the complete COMET-PEAK data set to a peer-reviewed journal for publication in due course.\nGSK and Vir are also partnering to investigate the use of sotrovimab in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection. GSK and Vir are supporting investigator-sponsored studies and fostering scientific collaborations with experienced investigators and networks involved in the continuum of care of immunocompromised patients, to understand the role sotrovimab for prophylaxis could play in this population. Discussions with regulatory authorities regarding the prophylaxis programme will take place in due course.\n\nAbout global access to sotrovimab\n\nSotrovimab is authorised for emergency use in the United States. Xevudy (sotrovimab) received apositive scientific opinionunder Article 5(3) of Regulation 726/2004 from the Committee for Human Medicinal Products (CHMP) in the EU, has been granted a provisional marketing authorisation in Australia, and conditional marketing authorisation in Saudi Arabia. In Japan, it has been approved via the Special Approval for Emergency Pathway. Temporary authorisations for sotrovimab have been granted in a dozen countries.\nGSK and Vir also recently submitted the Marketing Authorisation Application (MAA) to the European Medicines Agency for Xevudy (sotrovimab) for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at risk of progressing to severe\nCOVID-19.\nSotrovimab is supplied in several countries worldwide, including through national agreements in the United States, United Kingdom, Japan, Australia, Canada, Singapore, Switzerland and United Arab Emirates. We have also signed a Joint Procurement Agreement with the European Commission to supply doses of sotrovimab. Additional agreements are yet to be announced due to confidentiality or regulatory requirements.\n\nSotrovimab in the United States\nThe following is a summary of information for sotrovimab. Healthcare providers in the U.S. should review the Fact Sheets for information about the authorised use of sotrovimab and mandatory requirements of the EUA. Please see theFood and Drug Administration (FDA) Letter of Authorization, fullFact Sheet for Healthcare Providers, and fullFact Sheet for Patients, Parents, and Caregivers.\nSotrovimab has been authorized by the U.S. FDA for the emergency use described below. Sotrovimab is not FDA-approved for this use.\nSotrovimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of sotrovimab under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.\nAuthorized Use\nThe U.S. FDA has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.\nLimitations of Authorized Use\nSotrovimab is not authorized for use in patients:\n\nwho are hospitalized due to COVID-19, OR\nwho require oxygen therapy due to COVID-19, OR\nwho require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity)\n\nBenefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID 19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID 19 requiring high flow oxygen or mechanical ventilation.\nImportant Safety Information\nCONTRAINDICATIONS\nSotrovimab is contraindicated in patients who have a history of anaphylaxis to sotrovimab or to any of the excipients in the formulation.\nWARNINGS AND PRECAUTIONS\nThere are limited clinical data available for sotrovimab. Serious and unexpected adverse events may occur that have not been previously reported with sotrovimab use.\nHypersensitivity Including Anaphylaxis and Infusion-Related Reactions\nSerious hypersensitivity reactions, including anaphylaxis, have been observed with administration of sotrovimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.\nInfusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of sotrovimab. These reactions may be severe or life threatening.\nSigns and symptoms of infusion-related reactions may include: fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions (eg, pre-syncope, syncope), dizziness and diaphoresis.\nConsider slowing or stopping the infusion and administer appropriate medications and/or supportive care if an infusion-related reaction occurs.\nHypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization.\nClinical Worsening After SARS-CoV-2 Monoclonal Antibody Administration\nClinical worsening of COVID‑19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (eg, atrial fibrillation, tachycardia, bradycardia), fatigue, and altered mental status. Some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID‑19.\nLimitations of Benefit and Potential for Risk in Patients with Severe COVID‑19\nBenefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation. Therefore, sotrovimab is not authorized for use in patients: who are hospitalized due to COVID‑19, OR who require oxygen therapy due to COVID‑19, OR who require an increase in baseline oxygen flow rate due to COVID‑19 in those on chronic oxygen therapy due to underlying non‑COVID‑19 related comorbidity.\nADVERSE EVENTS\nHypersensitivity adverse reactions have been observed in 2% of patients treated with sotrovimab and 1% with placebo in COMET-ICE.\nThe most common treatment-emergent adverse events observed in the sotrovimab treatment group in COMET-ICE were rash (1%) and diarrhea (2%), all of which were Grade 1 (mild) or Grade 2 (moderate). No other treatment-emergent adverse events were reported at a higher rate with sotrovimab compared to placebo.\nUSE IN SPECIFIC POPULATIONS\nPregnancy\nThere are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome. Sotrovimab should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus.\nLactation\nThere are no available data on the presence of sotrovimab in human milk, the effects on the breastfed infant, or the effects on milk production. Individuals with COVID-19 who are breastfeeding should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.\nAbout the GSK and Vir collaboration\nIn April 2020, GSK and Vir entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.\nGSK commitment to tackling COVID-19\nGSK’s response to COVID-19 has been one of the broadest in the industry, with potential treatments in addition to our vaccine candidates in development with partner organisations.\nGSK is collaborating with several organisations on COVID-19 vaccines by providing access to our adjuvant technology. We are working with Sanofi S.A., Medicago Inc. and SK bioscience Co., Ltd. to develop adjuvanted, protein-based vaccine candidates, and all are now in Phase III clinical trials. The use of an adjuvant can be of particular importance in a pandemic since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and contributing to protecting more people in need.\nGSK is also working with mRNA specialist, CureVac N.V., to jointly develop next-generation, optimised mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine.\nGSK is also exploring treatments for COVID-19 patients, collaborating with Vir Biotechnology to investigate monoclonal antibodies that could be used as therapeutic or preventive options for COVID-19.\nVir’s commitment to COVID-19\nVir was founded with the mission of addressing the world’s most serious infectious diseases. In 2020, Vir responded rapidly to the COVID-19 pandemic by leveraging our unique scientific insights and industry-leading antibody platform to explore multiple monoclonal antibodies as potential therapeutic or preventive options for COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir advanced into the clinic. It was carefully selected for its demonstrated promise in preclinical research, including an anticipated high barrier to resistance and potential ability to both block the virus from entering healthy cells and clear infected cells. Vir is continuing to pursue novel therapeutic and prophylactic solutions to combat SARS-CoV-2 and future coronavirus pandemics, both independently and in collaboration with its partners.","news_type":1},"isVote":1,"tweetType":1,"viewCount":103,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603296703,"gmtCreate":1638410588424,"gmtModify":1638411653816,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>Wow nice ","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>Wow nice ","text":"$NIO Inc.(NIO)$Wow nice","images":[{"img":"https://static.tigerbbs.com/3a0591c0af408d2bcb44249410443119","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603296703","isVote":1,"tweetType":1,"viewCount":242,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":603296500,"gmtCreate":1638410565001,"gmtModify":1638411652143,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TWTR\">$Twitter(TWTR)$</a>Bit by bit ","listText":"<a href=\"https://laohu8.com/S/TWTR\">$Twitter(TWTR)$</a>Bit by bit ","text":"$Twitter(TWTR)$Bit by bit","images":[{"img":"https://static.tigerbbs.com/b931c06a48ec84e2f073e462cba6d3a2","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603296500","isVote":1,"tweetType":1,"viewCount":282,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":603206701,"gmtCreate":1638409788671,"gmtModify":1638410379523,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Thanks ","listText":"Thanks ","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603206701","repostId":"1187224831","repostType":4,"repost":{"id":"1187224831","pubTimestamp":1638405154,"share":"https://www.laohu8.com/m/news/1187224831?lang=&edition=full","pubTime":"2021-12-02 08:32","market":"sg","language":"en","title":"Singapore Stocks to watch: SPH, SPH Reit, Keppel, Sembcorp, Ntegrator","url":"https://stock-news.laohu8.com/highlight/detail?id=1187224831","media":"businesstimes","summary":"THE following companies saw new developments that may affect trading of their securities on Thursday","content":"<div>\n<p>THE following companies saw new developments that may affect trading of their securities on Thursday (Dec 2):\nSingapore Press Holdings (SPH), SPH Reit: In a bourse filing on Wednesday (Dec 1) night, ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/stocks/stocks-to-watch-sph-sph-reit-keppel-sembcorp-ntegrator\">Web Link</a>\n\n</div>\n","source":"lsy1607307803821","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore Stocks to watch: SPH, SPH Reit, Keppel, Sembcorp, Ntegrator</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore Stocks to watch: SPH, SPH Reit, Keppel, Sembcorp, Ntegrator\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-02 08:32 GMT+8 <a href=https://www.businesstimes.com.sg/stocks/stocks-to-watch-sph-sph-reit-keppel-sembcorp-ntegrator><strong>businesstimes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>THE following companies saw new developments that may affect trading of their securities on Thursday (Dec 2):\nSingapore Press Holdings (SPH), SPH Reit: In a bourse filing on Wednesday (Dec 1) night, ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/stocks/stocks-to-watch-sph-sph-reit-keppel-sembcorp-ntegrator\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数","BN4.SI":"吉宝有限公司","U96.SI":"胜科工业","SK6U.SI":"百利宫房地产投资信托","Q01.SI":"佳福"},"source_url":"https://www.businesstimes.com.sg/stocks/stocks-to-watch-sph-sph-reit-keppel-sembcorp-ntegrator","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1187224831","content_text":"THE following companies saw new developments that may affect trading of their securities on Thursday (Dec 2):\nSingapore Press Holdings (SPH), SPH Reit: In a bourse filing on Wednesday (Dec 1) night, SPH said its entire media-related business, including 2,500 employees, have been transferred to SPH Media Trust, a company limited by guarantee, for a nominal consideration of S$1. Following the completion, SPH will no longer have to meet the requirements imposed on newspaper companies under the Newspaper and Printing Presses Act in Singapore. SPH's shares closed up S$0.01 or 0.4 per cent to S$2.34 on Wednesday before the announcement, while shares for SPH Reit went up 0.5 per cent, or S$0.005 to close at S$1.\nKeppel Corporation: Its partially-owned subsidiary M1, said on Wednesday (Dec 1) that it will acquire up to 70 per cent of Malaysia-based Glocomp Systems and its 2 affiliate companies for RM111 million (S$36 million) through its indirect subsidiary AsiaPac Technology. In a separate statement, Keppel said AsiaPac will acquire an initial 26 per cent stake in Glocomp for RM26.3 million, funded via a combination of subscription of new ordinary shares to be issued by Glocomp, and purchase of ordinary shares from Glocomp founders Liew Yoon Kit, Giam Teck Eng, Chan Yue Mun and Chan Tze Ming. Keppel shares closed up S$0.01 or 0.2 per cent to S$5.11 on Wednesday.\nSembcorp Industries: The conglomerate on Thursday (Dec 2) said it is acquiring a 35 per cent interest in SDIC New Energy, a power company in China with a portfolio of 30 operational wind and solar photovoltaic assets, for an equity consideration of 1.5 billion yuan (S$320 million). Shares of Sembcorp closed at S$1.93 on Wednesday (Dec 1), up S$0.05 or 2.7 per cent.\nNtegrator International: The communications network specialist secured an S$8.6 million contract extension from a regional telecom provider for pipe installation and maintenance works in eastern, northern and western Singapore. The Catalist-listed group said in a bourse filing on Wednesday (Dec 1) that this deal adds to its order book of S$65.9 million as at Jun 30, 2021. Shares of thinly-traded Ntegrator ended Wednesday unchanged at S$0.007, before the announcement.\nTrading halt: Bread specialist QAF has called for a trading halt on Thursday (Dec 2) morning, pending an announcement. Shares of the counter closed at S$0.875, up 1.7 per cent or S$0.015, on Wednesday (Dec 1).","news_type":1},"isVote":1,"tweetType":1,"viewCount":148,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":601210045,"gmtCreate":1638533688808,"gmtModify":1638533703139,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good ","listText":"Good ","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/601210045","repostId":"1144924535","repostType":4,"repost":{"id":"1144924535","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据,旨在帮助投资者理解世界,做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638533072,"share":"https://www.laohu8.com/m/news/1144924535?lang=&edition=full","pubTime":"2021-12-03 20:04","market":"us","language":"en","title":"Moderna stock jumped more than 5% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1144924535","media":"老虎资讯综合","summary":"Moderna stock jumped more than 5% in premarket trading because Moderna led with antibody response in","content":"<p>Moderna stock jumped more than 5% in premarket trading because Moderna led with antibody response in COVID-19 booster trial in U.K..</p>\n<p><img src=\"https://static.tigerbbs.com/7b43bf58e1f0e28dcfc0f4c263ef6736\" tg-width=\"853\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p>According to a peer-reviewed study published in <i>The Lancet</i> on Thursday, Moderna COVID-19 vaccine has shown the strongest antibody effect in a trial that evaluated the different combinations of COVID-19 vaccines as boosters.</p>\n<p>The Phase 2 \"COV-Boost\" study conducted across 18 different U.K. locations involved nearly 2,900 individuals aged over 30 years. Half in the study had received two doses of Oxford-AstraZeneca vaccine, and the rest had received the Pfizer/BioNTec vaccine.</p>\n<p>The trial was designed to evaluate the safety and efficacy of seven booster vaccines developed by AstraZeneca, Pfizer/ BioNTech, Novavax, Johnson & Johnson, Moderna, Valneva and Curevac.</p>\n<p>While all seven vaccines except Valneva’s (VALN) boosted immunity in those who had received initial doses of Pfizer/ BioNTech, all seven had upped the immunity level when given 10 – 12 weeks after the initial regimen of the AstraZeneca vaccine.</p>\n<p>Notably, Moderna COVID-19 shot had generated the strongest booster effect leading to an over 32-fold rise in antibody level in the AstraZeneca group and over 11-fold increase in the Pfizer/ BioNTech group, <i>The Guardian</i> reported.</p>\n<p>In addition,Britain said on Wednesday it had agreed deals to buy 114 million more Pfizer/BioNTech and Moderna COVID-19 vaccine shots, saying it had sped up signing the new contracts in light of the emergence of the new Omicron variant.</p>\n<p>The deal involves an additional 60 million Moderna shots and 54 million Pfizer doses for next year and 2023, and will also include access to any modified vaccinations if they are needed to combat the Omicron strain or any other variant, the British health ministry said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock jumped more than 5% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock jumped more than 5% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-12-03 20:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna stock jumped more than 5% in premarket trading because Moderna led with antibody response in COVID-19 booster trial in U.K..</p>\n<p><img src=\"https://static.tigerbbs.com/7b43bf58e1f0e28dcfc0f4c263ef6736\" tg-width=\"853\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p>According to a peer-reviewed study published in <i>The Lancet</i> on Thursday, Moderna COVID-19 vaccine has shown the strongest antibody effect in a trial that evaluated the different combinations of COVID-19 vaccines as boosters.</p>\n<p>The Phase 2 \"COV-Boost\" study conducted across 18 different U.K. locations involved nearly 2,900 individuals aged over 30 years. Half in the study had received two doses of Oxford-AstraZeneca vaccine, and the rest had received the Pfizer/BioNTec vaccine.</p>\n<p>The trial was designed to evaluate the safety and efficacy of seven booster vaccines developed by AstraZeneca, Pfizer/ BioNTech, Novavax, Johnson & Johnson, Moderna, Valneva and Curevac.</p>\n<p>While all seven vaccines except Valneva’s (VALN) boosted immunity in those who had received initial doses of Pfizer/ BioNTech, all seven had upped the immunity level when given 10 – 12 weeks after the initial regimen of the AstraZeneca vaccine.</p>\n<p>Notably, Moderna COVID-19 shot had generated the strongest booster effect leading to an over 32-fold rise in antibody level in the AstraZeneca group and over 11-fold increase in the Pfizer/ BioNTech group, <i>The Guardian</i> reported.</p>\n<p>In addition,Britain said on Wednesday it had agreed deals to buy 114 million more Pfizer/BioNTech and Moderna COVID-19 vaccine shots, saying it had sped up signing the new contracts in light of the emergence of the new Omicron variant.</p>\n<p>The deal involves an additional 60 million Moderna shots and 54 million Pfizer doses for next year and 2023, and will also include access to any modified vaccinations if they are needed to combat the Omicron strain or any other variant, the British health ministry said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144924535","content_text":"Moderna stock jumped more than 5% in premarket trading because Moderna led with antibody response in COVID-19 booster trial in U.K..\n\nAccording to a peer-reviewed study published in The Lancet on Thursday, Moderna COVID-19 vaccine has shown the strongest antibody effect in a trial that evaluated the different combinations of COVID-19 vaccines as boosters.\nThe Phase 2 \"COV-Boost\" study conducted across 18 different U.K. locations involved nearly 2,900 individuals aged over 30 years. Half in the study had received two doses of Oxford-AstraZeneca vaccine, and the rest had received the Pfizer/BioNTec vaccine.\nThe trial was designed to evaluate the safety and efficacy of seven booster vaccines developed by AstraZeneca, Pfizer/ BioNTech, Novavax, Johnson & Johnson, Moderna, Valneva and Curevac.\nWhile all seven vaccines except Valneva’s (VALN) boosted immunity in those who had received initial doses of Pfizer/ BioNTech, all seven had upped the immunity level when given 10 – 12 weeks after the initial regimen of the AstraZeneca vaccine.\nNotably, Moderna COVID-19 shot had generated the strongest booster effect leading to an over 32-fold rise in antibody level in the AstraZeneca group and over 11-fold increase in the Pfizer/ BioNTech group, The Guardian reported.\nIn addition,Britain said on Wednesday it had agreed deals to buy 114 million more Pfizer/BioNTech and Moderna COVID-19 vaccine shots, saying it had sped up signing the new contracts in light of the emergence of the new Omicron variant.\nThe deal involves an additional 60 million Moderna shots and 54 million Pfizer doses for next year and 2023, and will also include access to any modified vaccinations if they are needed to combat the Omicron strain or any other variant, the British health ministry said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":323,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873461782,"gmtCreate":1636978021684,"gmtModify":1636978022119,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/S68.SI\">$SINGAPORE EXCHANGE LIMITED(S68.SI)$</a>Ddd","listText":"<a href=\"https://laohu8.com/S/S68.SI\">$SINGAPORE EXCHANGE LIMITED(S68.SI)$</a>Ddd","text":"$SINGAPORE EXCHANGE LIMITED(S68.SI)$Ddd","images":[{"img":"https://static.tigerbbs.com/516b780597444df30d5763000807b54b","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/873461782","isVote":1,"tweetType":1,"viewCount":347,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":861873972,"gmtCreate":1632488121596,"gmtModify":1632718459090,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/861873972","repostId":"1142559059","repostType":4,"isVote":1,"tweetType":1,"viewCount":50,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605854787,"gmtCreate":1639147765076,"gmtModify":1639147766866,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Down ","listText":"Down ","text":"Down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605854787","repostId":"1148141788","repostType":4,"repost":{"id":"1148141788","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639147224,"share":"https://www.laohu8.com/m/news/1148141788?lang=&edition=full","pubTime":"2021-12-10 22:40","market":"us","language":"en","title":"Vaccine stocks dropped in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1148141788","media":"Tiger Newspress","summary":"Vaccine stocks dropped in morning trading.Moderna,BioNTech and Novavax fell between 2% and 11%.","content":"<p>Vaccine stocks dropped in morning trading.Moderna,BioNTech and Novavax fell between 2% and 11%.</p>\n<p><img src=\"https://static.tigerbbs.com/d3f84cfc9f83b59cf14210d41d97111a\" tg-width=\"415\" tg-height=\"302\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine stocks dropped in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine stocks dropped in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-10 22:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vaccine stocks dropped in morning trading.Moderna,BioNTech and Novavax fell between 2% and 11%.</p>\n<p><img src=\"https://static.tigerbbs.com/d3f84cfc9f83b59cf14210d41d97111a\" tg-width=\"415\" tg-height=\"302\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148141788","content_text":"Vaccine stocks dropped in morning trading.Moderna,BioNTech and Novavax fell between 2% and 11%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":463,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603173105,"gmtCreate":1638382301257,"gmtModify":1638382302879,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ja ","listText":"Ja ","text":"Ja","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/603173105","repostId":"1167889898","repostType":4,"repost":{"id":"1167889898","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638372370,"share":"https://www.laohu8.com/m/news/1167889898?lang=&edition=full","pubTime":"2021-12-01 23:26","market":"us","language":"en","title":"Social media stocks jumped in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1167889898","media":"Tiger Newspress","summary":"Social media stocks jumped in morning trading.Snap,Twitter,Match,Bumble climbed between 3% and 6%.\n\n","content":"<p>Social media stocks jumped in morning trading.Snap,Twitter,Match,Bumble climbed between 3% and 6%.</p>\n<p><img src=\"https://static.tigerbbs.com/43d7ed750f9c250d3c0ae426133e8935\" tg-width=\"400\" tg-height=\"305\" referrerpolicy=\"no-referrer\"></p>\n<p>Cathie Wood's ARK Investment Management bought more than a million shares of Twitter Inc, a day after Jack Dorsey stepped down as the chief executive of the social networking site;</p>\n<p>Match Group to pay over $400 million to settle Tinder valuation case.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Social media stocks jumped in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSocial media stocks jumped in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-01 23:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Social media stocks jumped in morning trading.Snap,Twitter,Match,Bumble climbed between 3% and 6%.</p>\n<p><img src=\"https://static.tigerbbs.com/43d7ed750f9c250d3c0ae426133e8935\" tg-width=\"400\" tg-height=\"305\" referrerpolicy=\"no-referrer\"></p>\n<p>Cathie Wood's ARK Investment Management bought more than a million shares of Twitter Inc, a day after Jack Dorsey stepped down as the chief executive of the social networking site;</p>\n<p>Match Group to pay over $400 million to settle Tinder valuation case.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MTCH":"Match Group, Inc.","PINS":"Pinterest, Inc.","SNAP":"Snap Inc","TWTR":"Twitter","BMBL":"Bumble Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167889898","content_text":"Social media stocks jumped in morning trading.Snap,Twitter,Match,Bumble climbed between 3% and 6%.\n\nCathie Wood's ARK Investment Management bought more than a million shares of Twitter Inc, a day after Jack Dorsey stepped down as the chief executive of the social networking site;\nMatch Group to pay over $400 million to settle Tinder valuation case.","news_type":1},"isVote":1,"tweetType":1,"viewCount":36,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877066485,"gmtCreate":1637844922961,"gmtModify":1637844923386,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Up","listText":"Up","text":"Up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877066485","repostId":"2185354679","repostType":4,"repost":{"id":"2185354679","pubTimestamp":1637831760,"share":"https://www.laohu8.com/m/news/2185354679?lang=&edition=full","pubTime":"2021-11-25 17:16","market":"us","language":"en","title":"3 Unstoppable Stocks You Can Buy Right Now for Less Than $100","url":"https://stock-news.laohu8.com/highlight/detail?id=2185354679","media":"Motley Fool","summary":"Do you like high growth at an introductory rate? Check out these three stocks.","content":"<p>Many investors get into trading stocks with the desire to find top stocks to buy into early in their growth cycle. That's not so easy to do these days when many stocks get hyped before they even reach the open markets and end up trading at high prices by the time you feel comfortable adding them to your portfolio.</p>\n<p>Still, there are occasional hidden gems in the market that are quietly gaining in growth and recognition, with shares still trading at relatively low prices. <b>Global-e Online</b> (NASDAQ:GLBE), <b>Revolve Group</b> (NYSE:RVLV), and <b><a href=\"https://laohu8.com/S/OPAD\">Offerpad Solutions</a></b> (NYSE:OPAD) are three stocks trading below $100 a share that are demonstrating show-stopping growth. Let's find out a bit more about them.</p>\n<h2>1. Global-e Online: It's a small world after all</h2>\n<p>Global-e Online offers cross-border payment solutions for online retailers. As more and more e-commerce companies expand into new markets and begin to offer international shipping, they begin to discover that there are challenges to making the process cost-effective and worth the investment.</p>\n<p>Global-e comes in to make the process easy, offering features that efficiently manage shipping options, local currencies, calculating customs, and international returns. It has two programs, <a href=\"https://laohu8.com/S/AONE.U\">one</a> for small businesses and one for larger-volume clients, as well as a program with <b><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a></b> (formerly Facebook) to assist the thousands of sellers using Facebook Marketplace.</p>\n<p>It works with some of the biggest online retailers in the world, including the biggest, French luxury conglomerate <b>LVMH</b>, as well as brands like cosmetic-giant Sephora Asia and French fashion house Givenchy. It also has strong exposure from its partnership with e-commerce master <b>Shopify</b>, through which it powers international commerce with many small and medium-sized brands operating through Shopify services.</p>\n<p>The company is ramping up its operations exponentially. In the third quarter, gross merchandise volume (GMV) grew 86% year over year to a record $352 million, and revenue increased 77% to a record $59 million. That was particularly impressive as e-commerce has begun to modulate after COVID-19 restrictions eased. Gross profit grew 127% year over year to $2 million, although Globel-e posted a $28.5 million loss after a $1.2 million profit last year. Much of the loss was related to increased expenses of scaling up operations specifically related to its Shopify integration.</p>\n<p>Global-e stock went public in May at $25 a share and is up 111% since then. It's not exactly cheap, trading at 43 times trailing-12-month sales, but shares cost $53 as of this writing. It's still a tiny company, with just over $200 million in trailing-12-month earnings. Investors can expect a lot from this high-growth company in the future.</p>\n<h2>2. Revolve Group: Not your typical fashion company</h2>\n<p>At first glance, Revolve Group's website doesn't look different than most other fashion-forward websites. But there's a reason this online fashion retailer that focuses on selling dresses and other apparel for social events is growing by leaps and bounds. That reason involves the underlying infrastructure that's supporting the company's operations. That infrastructure includes 18 years' worth of data supplying its technology-backed artificial intelligence, a modern approach to e-commerce that includes partnerships with influencers and thousands of brands that appeal to its Gen X target consumer.</p>\n<p>Third-quarter sales increased 62% year over year to $244 million, an acceleration from the second quarter. Net income decreased 14% year over year as the company scales, but posting a profit is a great sign from a growth company.</p>\n<p>International sales made up 19% of the total, which is an unusually high number. Its technology supports international sales, and that opens up its addressable market.</p>\n<p>Revolve Group stock is up 160% year to date and shares trade at 66 times trailing-12-month earnings at a current price of $81 a share. But that price won't last long as investors scoop up shares of this high-growth stock.</p>\n<h2>3. Offerpad: Chasing a $1.9 trillion market opportunity</h2>\n<p>Offerpad wants to buy your house for cash before you list it with a Realtor. Then it wants to renovate and flip it, making money in the process. It's a model called ibuying and it's becoming more popular and may soon become the standard in the U.S. real estate market.</p>\n<p>The company's management sees a massive $1.9 trillion opportunity in the housing market, of which only 1% is now online. It has a $1 trillion market in what it calls the \"buy box today\" market, which are U.S. homes for sale that cost up to $750,000.</p>\n<p>Many readers know that <b><a href=\"https://laohu8.com/S/Z\">Zillow</a> Group</b> just bowed out of this market, but it's not clear that there's something wrong with the market or just something wrong with Zillow's ibuying operations. Competitors like Offerpad and <b>Opendoor Technologies</b> are posting high growth, and while investors should do their own research, they shouldn't be scared off from the industry.</p>\n<p>In the third quarter, Offerpad revenue increased 190% year over year to $540 million, and gross profit increased 160% to $53 million. The company sold 1,673 homes, or more than double year over year, and raised its outlook to a midpoint of $1.88 billion in total 2021 sales. Net loss for the quarter expanded from $3 million in 2020 to $15 million in 2021.</p>\n<p>Offerpad stock went public almost a year ago, and shares are down 34.5% year to date, trading around $7.20 a share as of this writing. There's risk involved in investing in this company since it deals with a capital-intensive model, losses are widening, and ibuying hasn't been proven to be a secure business yet. But at this price and with its current growth rates, Offerpad might be a stock to consider for your portfolio.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Stocks You Can Buy Right Now for Less Than $100</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Stocks You Can Buy Right Now for Less Than $100\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-25 17:16 GMT+8 <a href=https://www.fool.com/investing/2021/11/24/3-unstoppable-stocks-can-buy-for-less-that-100/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Many investors get into trading stocks with the desire to find top stocks to buy into early in their growth cycle. That's not so easy to do these days when many stocks get hyped before they even reach...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/24/3-unstoppable-stocks-can-buy-for-less-that-100/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RVLV":"Revolve Group, LLC","BK4122":"互联网与直销零售","OPAD":"Offerpad Solutions","BK4539":"次新股","GLBE":"Global-E Online Ltd."},"source_url":"https://www.fool.com/investing/2021/11/24/3-unstoppable-stocks-can-buy-for-less-that-100/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185354679","content_text":"Many investors get into trading stocks with the desire to find top stocks to buy into early in their growth cycle. That's not so easy to do these days when many stocks get hyped before they even reach the open markets and end up trading at high prices by the time you feel comfortable adding them to your portfolio.\nStill, there are occasional hidden gems in the market that are quietly gaining in growth and recognition, with shares still trading at relatively low prices. Global-e Online (NASDAQ:GLBE), Revolve Group (NYSE:RVLV), and Offerpad Solutions (NYSE:OPAD) are three stocks trading below $100 a share that are demonstrating show-stopping growth. Let's find out a bit more about them.\n1. Global-e Online: It's a small world after all\nGlobal-e Online offers cross-border payment solutions for online retailers. As more and more e-commerce companies expand into new markets and begin to offer international shipping, they begin to discover that there are challenges to making the process cost-effective and worth the investment.\nGlobal-e comes in to make the process easy, offering features that efficiently manage shipping options, local currencies, calculating customs, and international returns. It has two programs, one for small businesses and one for larger-volume clients, as well as a program with Meta Platforms (formerly Facebook) to assist the thousands of sellers using Facebook Marketplace.\nIt works with some of the biggest online retailers in the world, including the biggest, French luxury conglomerate LVMH, as well as brands like cosmetic-giant Sephora Asia and French fashion house Givenchy. It also has strong exposure from its partnership with e-commerce master Shopify, through which it powers international commerce with many small and medium-sized brands operating through Shopify services.\nThe company is ramping up its operations exponentially. In the third quarter, gross merchandise volume (GMV) grew 86% year over year to a record $352 million, and revenue increased 77% to a record $59 million. That was particularly impressive as e-commerce has begun to modulate after COVID-19 restrictions eased. Gross profit grew 127% year over year to $2 million, although Globel-e posted a $28.5 million loss after a $1.2 million profit last year. Much of the loss was related to increased expenses of scaling up operations specifically related to its Shopify integration.\nGlobal-e stock went public in May at $25 a share and is up 111% since then. It's not exactly cheap, trading at 43 times trailing-12-month sales, but shares cost $53 as of this writing. It's still a tiny company, with just over $200 million in trailing-12-month earnings. Investors can expect a lot from this high-growth company in the future.\n2. Revolve Group: Not your typical fashion company\nAt first glance, Revolve Group's website doesn't look different than most other fashion-forward websites. But there's a reason this online fashion retailer that focuses on selling dresses and other apparel for social events is growing by leaps and bounds. That reason involves the underlying infrastructure that's supporting the company's operations. That infrastructure includes 18 years' worth of data supplying its technology-backed artificial intelligence, a modern approach to e-commerce that includes partnerships with influencers and thousands of brands that appeal to its Gen X target consumer.\nThird-quarter sales increased 62% year over year to $244 million, an acceleration from the second quarter. Net income decreased 14% year over year as the company scales, but posting a profit is a great sign from a growth company.\nInternational sales made up 19% of the total, which is an unusually high number. Its technology supports international sales, and that opens up its addressable market.\nRevolve Group stock is up 160% year to date and shares trade at 66 times trailing-12-month earnings at a current price of $81 a share. But that price won't last long as investors scoop up shares of this high-growth stock.\n3. Offerpad: Chasing a $1.9 trillion market opportunity\nOfferpad wants to buy your house for cash before you list it with a Realtor. Then it wants to renovate and flip it, making money in the process. It's a model called ibuying and it's becoming more popular and may soon become the standard in the U.S. real estate market.\nThe company's management sees a massive $1.9 trillion opportunity in the housing market, of which only 1% is now online. It has a $1 trillion market in what it calls the \"buy box today\" market, which are U.S. homes for sale that cost up to $750,000.\nMany readers know that Zillow Group just bowed out of this market, but it's not clear that there's something wrong with the market or just something wrong with Zillow's ibuying operations. Competitors like Offerpad and Opendoor Technologies are posting high growth, and while investors should do their own research, they shouldn't be scared off from the industry.\nIn the third quarter, Offerpad revenue increased 190% year over year to $540 million, and gross profit increased 160% to $53 million. The company sold 1,673 homes, or more than double year over year, and raised its outlook to a midpoint of $1.88 billion in total 2021 sales. Net loss for the quarter expanded from $3 million in 2020 to $15 million in 2021.\nOfferpad stock went public almost a year ago, and shares are down 34.5% year to date, trading around $7.20 a share as of this writing. There's risk involved in investing in this company since it deals with a capital-intensive model, losses are widening, and ibuying hasn't been proven to be a secure business yet. But at this price and with its current growth rates, Offerpad might be a stock to consider for your portfolio.","news_type":1},"isVote":1,"tweetType":1,"viewCount":29,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877830687,"gmtCreate":1637909438458,"gmtModify":1637909438917,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FB\">$Meta Platforms, Inc.(FB)$</a>Tyy","listText":"<a href=\"https://laohu8.com/S/FB\">$Meta Platforms, Inc.(FB)$</a>Tyy","text":"$Meta Platforms, Inc.(FB)$Tyy","images":[{"img":"https://static.tigerbbs.com/a27363e570315992f30322e0f71366a5","width":"1125","height":"3331"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877830687","isVote":1,"tweetType":1,"viewCount":228,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":876163590,"gmtCreate":1637283223180,"gmtModify":1637283264894,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/876163590","repostId":"1185082595","repostType":4,"repost":{"id":"1185082595","pubTimestamp":1637276340,"share":"https://www.laohu8.com/m/news/1185082595?lang=&edition=full","pubTime":"2021-11-19 06:59","market":"us","language":"en","title":"S&P 500, Nasdaq hit record closing highs","url":"https://stock-news.laohu8.com/highlight/detail?id=1185082595","media":"Reuters","summary":"(Reuters) - The S&P 500 and Nasdaq notched record closing highs on Thursday, boosted by upbeat corpo","content":"<p>(Reuters) - The S&P 500 and Nasdaq notched record closing highs on Thursday, boosted by upbeat corporate earnings news from companies including <a href=\"https://laohu8.com/S/NVDA\">Nvidia</a>, while Turkey's lira weakened further after its central bank cut rates.</p>\n<p>MSCI's gauge of stocks across the globe was flat, and the Dow Jones industrial average ended lower.Nvidia's stock jumped and was among the biggest supports for the S&P 500 and Nasdaq after it beat quarterly estimates and forecast strong fourth-quarter revenue. Macy's(M.N)shares shot up 21.2% after it raised its earnings outlook.</p>\n<p>On the flip side, <a href=\"https://laohu8.com/S/CSCO\">Cisco Systems</a> shares fell 5.5%, a day after it forecast current-quarter revenue below expectations due to supply chain shortages and delays. It was the latest in a growing list of U.S. companies citing supply chain problems.</p>\n<p>Investors have been concerned over further increases in price pressures. Retail giant <a href=\"https://laohu8.com/S/TGT\">Target</a> warned of higher costs earlier this week.</p>\n<p>New York Federal Reserve Bank President John Williams said Thursday that inflation is becoming more broad-based and that expectations for future price increases are rising.</p>\n<p>The Dow Jones Industrial Average(.DJI) fell 60.1 points, or 0.17%, to 35,870.95, the S&P 500(.SPX)gained 15.87 points, or 0.34%, to 4,704.54 and the Nasdaq Composite(.IXIC) added 72.14 points, or 0.45%, to 15,993.71.</p>\n<p>The pan-European STOXX 600 index(.STOXX)lost 0.46% and MSCI's gauge of stocks across the globe(.MIWD00000PUS)gained 0.03%.</p>\n<p>Turkey's lira shed another 2.83% after its central bank cut rates by 100 basis points to 15%, even in the face of inflation near 20%, sending the Turkish currency hurtling southward.</p>\n<p>\"The lira remains a punching bag, and further weakness has no end in sight,\" said Edward Moya, senior market analyst at Oanda.</p>\n<p>The lira has lost around 11.5% of its value this month amid President Tayyip Erdogan's renewed criticism of interest rates and calls for stimulus despite the risks. It was last at 10.909, having earlier hit a record low of 11.30 per dollar.</p>\n<p>The dollar edged back from a 16-month high as traders weighed whether the U.S. currency's recent surge had gone too far.</p>\n<p>The dollar index , which measures the currency against a basket of six rivals, was last down 0.3%.</p>\n<p>In the U.S. Treasury market, yields fell after the relative success of a 20-year bond auction on Wednesday reduced fears about further rapid yield increases.</p>\n<p>Benchmark 10-year notes were last at 1.587%. They have jumped from a low of 1.415% last week and are holding below five-month highs of 1.705% reached on Oct. 21.</p>\n<p>Oil prices rose slightly after dropping to six-week lows.</p>\n<p>Brent crude settled up 96 cents, or 1.2%, at $81.24 a barrel, while U.S. West Texas Intermediate crude futures closed 65 cents, or 0.8%, higher at $79.01.</p>\n<p>U.S. gold futures settled down 0.5% at $1,861.4.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500, Nasdaq hit record closing highs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500, Nasdaq hit record closing highs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-19 06:59 GMT+8 <a href=https://www.reuters.com/markets/us/global-markets-wrapup-6-graphics-2021-11-18/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - The S&P 500 and Nasdaq notched record closing highs on Thursday, boosted by upbeat corporate earnings news from companies including Nvidia, while Turkey's lira weakened further after its ...</p>\n\n<a href=\"https://www.reuters.com/markets/us/global-markets-wrapup-6-graphics-2021-11-18/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/markets/us/global-markets-wrapup-6-graphics-2021-11-18/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1185082595","content_text":"(Reuters) - The S&P 500 and Nasdaq notched record closing highs on Thursday, boosted by upbeat corporate earnings news from companies including Nvidia, while Turkey's lira weakened further after its central bank cut rates.\nMSCI's gauge of stocks across the globe was flat, and the Dow Jones industrial average ended lower.Nvidia's stock jumped and was among the biggest supports for the S&P 500 and Nasdaq after it beat quarterly estimates and forecast strong fourth-quarter revenue. Macy's(M.N)shares shot up 21.2% after it raised its earnings outlook.\nOn the flip side, Cisco Systems shares fell 5.5%, a day after it forecast current-quarter revenue below expectations due to supply chain shortages and delays. It was the latest in a growing list of U.S. companies citing supply chain problems.\nInvestors have been concerned over further increases in price pressures. Retail giant Target warned of higher costs earlier this week.\nNew York Federal Reserve Bank President John Williams said Thursday that inflation is becoming more broad-based and that expectations for future price increases are rising.\nThe Dow Jones Industrial Average(.DJI) fell 60.1 points, or 0.17%, to 35,870.95, the S&P 500(.SPX)gained 15.87 points, or 0.34%, to 4,704.54 and the Nasdaq Composite(.IXIC) added 72.14 points, or 0.45%, to 15,993.71.\nThe pan-European STOXX 600 index(.STOXX)lost 0.46% and MSCI's gauge of stocks across the globe(.MIWD00000PUS)gained 0.03%.\nTurkey's lira shed another 2.83% after its central bank cut rates by 100 basis points to 15%, even in the face of inflation near 20%, sending the Turkish currency hurtling southward.\n\"The lira remains a punching bag, and further weakness has no end in sight,\" said Edward Moya, senior market analyst at Oanda.\nThe lira has lost around 11.5% of its value this month amid President Tayyip Erdogan's renewed criticism of interest rates and calls for stimulus despite the risks. It was last at 10.909, having earlier hit a record low of 11.30 per dollar.\nThe dollar edged back from a 16-month high as traders weighed whether the U.S. currency's recent surge had gone too far.\nThe dollar index , which measures the currency against a basket of six rivals, was last down 0.3%.\nIn the U.S. Treasury market, yields fell after the relative success of a 20-year bond auction on Wednesday reduced fears about further rapid yield increases.\nBenchmark 10-year notes were last at 1.587%. They have jumped from a low of 1.415% last week and are holding below five-month highs of 1.705% reached on Oct. 21.\nOil prices rose slightly after dropping to six-week lows.\nBrent crude settled up 96 cents, or 1.2%, at $81.24 a barrel, while U.S. West Texas Intermediate crude futures closed 65 cents, or 0.8%, higher at $79.01.\nU.S. gold futures settled down 0.5% at $1,861.4.","news_type":1},"isVote":1,"tweetType":1,"viewCount":15,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846087664,"gmtCreate":1636035429898,"gmtModify":1636035431319,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"$🍀🍀🍀","listText":"$🍀🍀🍀","text":"$🍀🍀🍀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/846087664","repostId":"1110474410","repostType":4,"repost":{"id":"1110474410","pubTimestamp":1636034860,"share":"https://www.laohu8.com/m/news/1110474410?lang=&edition=full","pubTime":"2021-11-04 22:07","market":"us","language":"en","title":"NeoPhotonics Stock Soars. It’s Being Acquired by Apple Supplier Lumentum.","url":"https://stock-news.laohu8.com/highlight/detail?id=1110474410","media":"Barrons","summary":"Laser manufacturer NeoPhotonics is being acquired by Lumentum in a bid by the Apple supplier to expa","content":"<p>Laser manufacturer NeoPhotonics is being acquired by Lumentum in a bid by the Apple supplier to expand its presence in high-speed optical networks.</p>\n<p>Lumentum (ticker: LITE) will pay NeoPhotonics (NPTN) stockholders $16 a share in an all-cash transaction. The deal is valued at about $918 million.</p>\n<p>“With NeoPhotonics, we’re making another important investment in better serving our customers and expanding our photonics capabilities at a time when photonics are at the forefront of favorable long-term market trends,” said Alan Lowe, Lumentum president and CEO.</p>\n<p>NeoPhotonics stock was soaring nearly 34% to $15.41 early Thursday. Shares of Lumentum dropped 1%.</p>\n<p>The acquisition will accelerate Lumentum’s exposure to the growing $10 billion market for high-speed cloud and telecom network infrastructure. Executives expect it will generate more than $50 million in annual synergies within 24 months from the deal closing.</p>\n<p>The deal is expected to close in the second half of 2022. In the meantime, Lumentum will provide up to $50 million in term loans to NeoPhotonics to fund anticipated growth.</p>\n<p>Lumentum is Apple’s main supplier of the 3D sensors the tech giant uses in its Face ID technology. Earlier this year, Lumentum bought out laser competitor Coherent in a $5.7 billion deal amid an ongoing consolidation wave in the optical components industry. Lumentum acquired Oclaro in 2018.</p>\n<p>Lumentum also reported fiscal first-quarter earnings on Thursday. Lumentum posted adjusted earnings of $1.79 a share on revenue of $448.4 million. Analysts were looking for profit of $1.55 a share on revenue of $439.5 million.</p>\n<p>NeoPhotonics develops and manufactures lasers used to transmit and receive digital signals for the cloud, internet content providers and telecom networks. One of the company’s biggest customer was Chinese technology manufacturer Huawei, but the business took a hit in August 2020 when the Department of Commerce imposed restrictions on Huawei. In the last quarter before the restrictions, Huawei accounted for about $40 million of revenue.</p>\n<p>The company has since made up for the loss, and reported earnings Thursday that beat analysts’ expectations. NeoPhotonics reported earnings of 1 cent a share on revenue of $83.7 million in its third quarter. Analysts surveyed by FactSet were expecting a loss of 4 cents a share on revenue of $79.9 million.</p>\n<p>“The increasing global demand for our ultra-pure light tunable lasers and photonics technologies for speed over distance applications is more apparent than ever, and Lumentum is the ideal partner to serve our customers on a larger scale,” said NeoPhotonics CEO Tim Jenks.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NeoPhotonics Stock Soars. It’s Being Acquired by Apple Supplier Lumentum.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeoPhotonics Stock Soars. It’s Being Acquired by Apple Supplier Lumentum.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-04 22:07 GMT+8 <a href=https://www.barrons.com/articles/neophotonics-stock-soars-lumentum-acquisition-51636034034?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Laser manufacturer NeoPhotonics is being acquired by Lumentum in a bid by the Apple supplier to expand its presence in high-speed optical networks.\nLumentum (ticker: LITE) will pay NeoPhotonics (NPTN)...</p>\n\n<a href=\"https://www.barrons.com/articles/neophotonics-stock-soars-lumentum-acquisition-51636034034?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LITE":"Lumentum Holdings Inc."},"source_url":"https://www.barrons.com/articles/neophotonics-stock-soars-lumentum-acquisition-51636034034?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1110474410","content_text":"Laser manufacturer NeoPhotonics is being acquired by Lumentum in a bid by the Apple supplier to expand its presence in high-speed optical networks.\nLumentum (ticker: LITE) will pay NeoPhotonics (NPTN) stockholders $16 a share in an all-cash transaction. The deal is valued at about $918 million.\n“With NeoPhotonics, we’re making another important investment in better serving our customers and expanding our photonics capabilities at a time when photonics are at the forefront of favorable long-term market trends,” said Alan Lowe, Lumentum president and CEO.\nNeoPhotonics stock was soaring nearly 34% to $15.41 early Thursday. Shares of Lumentum dropped 1%.\nThe acquisition will accelerate Lumentum’s exposure to the growing $10 billion market for high-speed cloud and telecom network infrastructure. Executives expect it will generate more than $50 million in annual synergies within 24 months from the deal closing.\nThe deal is expected to close in the second half of 2022. In the meantime, Lumentum will provide up to $50 million in term loans to NeoPhotonics to fund anticipated growth.\nLumentum is Apple’s main supplier of the 3D sensors the tech giant uses in its Face ID technology. Earlier this year, Lumentum bought out laser competitor Coherent in a $5.7 billion deal amid an ongoing consolidation wave in the optical components industry. Lumentum acquired Oclaro in 2018.\nLumentum also reported fiscal first-quarter earnings on Thursday. Lumentum posted adjusted earnings of $1.79 a share on revenue of $448.4 million. Analysts were looking for profit of $1.55 a share on revenue of $439.5 million.\nNeoPhotonics develops and manufactures lasers used to transmit and receive digital signals for the cloud, internet content providers and telecom networks. One of the company’s biggest customer was Chinese technology manufacturer Huawei, but the business took a hit in August 2020 when the Department of Commerce imposed restrictions on Huawei. In the last quarter before the restrictions, Huawei accounted for about $40 million of revenue.\nThe company has since made up for the loss, and reported earnings Thursday that beat analysts’ expectations. NeoPhotonics reported earnings of 1 cent a share on revenue of $83.7 million in its third quarter. Analysts surveyed by FactSet were expecting a loss of 4 cents a share on revenue of $79.9 million.\n“The increasing global demand for our ultra-pure light tunable lasers and photonics technologies for speed over distance applications is more apparent than ever, and Lumentum is the ideal partner to serve our customers on a larger scale,” said NeoPhotonics CEO Tim Jenks.","news_type":1},"isVote":1,"tweetType":1,"viewCount":84,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862635023,"gmtCreate":1632874652029,"gmtModify":1632874652352,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/862635023","repostId":"1106892312","repostType":4,"repost":{"id":"1106892312","pubTimestamp":1632870830,"share":"https://www.laohu8.com/m/news/1106892312?lang=&edition=full","pubTime":"2021-09-29 07:13","market":"us","language":"en","title":"These high-flying stocks of 2021 dropped the most on Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1106892312","media":"marketwatch","summary":"Stocks hit especially hard include Moderna, Nvidia and Google holding company Alphabet.\n\nThe Federal","content":"<blockquote>\n <b>Stocks hit especially hard include Moderna, Nvidia and Google holding company Alphabet.</b>\n</blockquote>\n<p>The Federal Reserve’s signaled policy change is having a predictable effect — pushing stock prices lower as bond yields become more attractive.</p>\n<p>This reverses some very strong action for U.S. stocks — at least for a day. Below is a list of 10 stocks that had increased at least 50% for 2021 through Sept. 27, but were pulled back the most on Sept. 28.</p>\n<p>The Dow Jones Industrial AverageDJIAdeclined 1.6%, while the S&P 500 IndexSPXfell 2%. The Nasdaq Composite IndexCOMPfared worst, tumbling 2.8%.</p>\n<p>The yield on 10-year U.S. Treasury notesBX:TMUBMUSD10Yincreased by 5 basis points to 1.55%. That was up from 1.33% only a week earlier.</p>\n<p>Combined, there are 523 stocks in the S&P 500 and Nasdaq-100NDXindexes. Among these stocks, 50 had risen at least 50% so far in 2021 through Sept. 27, excluding dividends, according to data provided by FactSet. Here are the 10 that declined the most on Sept. 28 — actually 11 stocks, as two common-share classes of Alphabet Inc.GOOGLGOOGare included:</p>\n<p><img src=\"https://static.tigerbbs.com/3e62aed3304cd811cf41ce390e38c41c\" tg-width=\"1106\" tg-height=\"713\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/83133c4cfdb3554d40f750a60c91892c\" tg-width=\"1101\" tg-height=\"291\" width=\"100%\" height=\"auto\">Click the tickers for more about each company. Clickhere for Tomi Kilgore’s detailed guide to the wealth of information available for free on the quote page.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These high-flying stocks of 2021 dropped the most on Tuesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese high-flying stocks of 2021 dropped the most on Tuesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-29 07:13 GMT+8 <a href=https://www.marketwatch.com/story/these-high-flying-stocks-of-2021-have-dropped-the-most-today-11632846406?mod=home-page><strong>marketwatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks hit especially hard include Moderna, Nvidia and Google holding company Alphabet.\n\nThe Federal Reserve’s signaled policy change is having a predictable effect — pushing stock prices lower as ...</p>\n\n<a href=\"https://www.marketwatch.com/story/these-high-flying-stocks-of-2021-have-dropped-the-most-today-11632846406?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯","SPY":"标普500ETF"},"source_url":"https://www.marketwatch.com/story/these-high-flying-stocks-of-2021-have-dropped-the-most-today-11632846406?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106892312","content_text":"Stocks hit especially hard include Moderna, Nvidia and Google holding company Alphabet.\n\nThe Federal Reserve’s signaled policy change is having a predictable effect — pushing stock prices lower as bond yields become more attractive.\nThis reverses some very strong action for U.S. stocks — at least for a day. Below is a list of 10 stocks that had increased at least 50% for 2021 through Sept. 27, but were pulled back the most on Sept. 28.\nThe Dow Jones Industrial AverageDJIAdeclined 1.6%, while the S&P 500 IndexSPXfell 2%. The Nasdaq Composite IndexCOMPfared worst, tumbling 2.8%.\nThe yield on 10-year U.S. Treasury notesBX:TMUBMUSD10Yincreased by 5 basis points to 1.55%. That was up from 1.33% only a week earlier.\nCombined, there are 523 stocks in the S&P 500 and Nasdaq-100NDXindexes. Among these stocks, 50 had risen at least 50% so far in 2021 through Sept. 27, excluding dividends, according to data provided by FactSet. Here are the 10 that declined the most on Sept. 28 — actually 11 stocks, as two common-share classes of Alphabet Inc.GOOGLGOOGare included:\nClick the tickers for more about each company. Clickhere for Tomi Kilgore’s detailed guide to the wealth of information available for free on the quote page.","news_type":1},"isVote":1,"tweetType":1,"viewCount":87,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605500663,"gmtCreate":1639186160836,"gmtModify":1639186161876,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"✅ ","listText":"✅ ","text":"✅","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605500663","repostId":"2190767366","repostType":4,"repost":{"id":"2190767366","pubTimestamp":1639171676,"share":"https://www.laohu8.com/m/news/2190767366?lang=&edition=full","pubTime":"2021-12-11 05:27","market":"hk","language":"en","title":"US STOCKS-Wall Street gains, S&P hits record closing high as CPI meets expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2190767366","media":"Reuters","summary":"(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news","content":"<p>(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.)</p>\n<p>* Annual CPI growth hits highest level in more than 39 years</p>\n<p>* S&P registers biggest weekly percentage gain since Feb</p>\n<p>* Oracle leaps on upbeat quarterly results, outlook</p>\n<p>* Broadcom gains on buyback plan announcement</p>\n<p>* Indexes up: Dow 0.60%, S&P 0.95%, Nasdaq 0.73% (Updates with closing prices, adds market details)</p>\n<p>NEW YORK, Dec 10 (Reuters) - Wall Street advanced on Friday and the S&P 500 notched an all-time closing high, as market participants digested an inflation reading that was in line with consensus, but also marked the largest annual increase in consumer prices in nearly four decades.</p>\n<p>All three major U.S. stock indexes advanced, with tech shares doing the heavy lifting.</p>\n<p>The indexes all ended the session higher than last Friday's close, and the benchmark S&P 500 posted its biggest weekly percentage advance since the week ended Feb. 5, as waning jitters over the Omicron coronavirus variant helped fuel a broad rally early in the week.</p>\n<p>A report from the Labor Department showed consumer prices surged last month to a 6.8% annual growth rate, the highest reading in more than 39 years.</p>\n<p>\"It would appear that today’s reaction would indicate the markets were discounting the (CPI) reading,\" said Chuck Carlson, chief executive officer at Horizon Investment Services in Hammond, Indiana. \"The markets are always looking forward and perhaps today's reading is indicative of a peak versus a sustained level.\"</p>\n<p>Persistent inflation due to ongoing supply-chain challenges suggests the U.S. Federal Reserve could very well start tightening its accommodative monetary policy sooner than many might have hoped.</p>\n<p>\"Clearly, it’s being driven primarily by supply-chain issues,\" Said Tim Ghriskey, senior portfolio strategist at Inverness Counsel in New York. \"But it appears these issues could be easing, and over time we should see them moderate. And that should take the foot off the inflation accelerator.\"</p>\n<p>A Reuters poll of economists sees the central bank hiking key interest rates from near zero to 0.25-0.50% in the third quarter of next year, followed by another in the fourth quarter.</p>\n<p>The Fed is expected to convene next week for its two-day monetary policy meeting, which market participants will be scrutinizing for any clues regarding those rate increases along with the pace at which it will taper its bond purchases.</p>\n<p>\"The Fed is has telegraphed on tightening sooner rather than later,\" Carlson added. \"The markets are more comfortable with Fed tightening if it reduces inflation expectations.\"</p>\n<p>The graphic below shows core CPI along with other major U.S. indicators, all of which continue to soar well above the Fed's average annual 2% inflation target:</p>\n<p>The Dow Jones Industrial Average rose 216.3 points, or 0.6%, to 35,970.99, the S&P 500 gained 44.57 points, or 0.95%, to 4,712.02 and the Nasdaq Composite added 113.23 points, or 0.73%, to 15,630.60.</p>\n<p>All 11 major sectors in the S&P 500 ended the session green, with technology and consumer staples enjoying the largest percentage jumps.</p>\n<p>Shares of software firm Oracle Corp jumped 15.6% after it forecast an upbeat third-quarter outlook.</p>\n<p>Broadcom Inc gained 8.3% following the chipmaker's announcement of a $10 billion share buyback plan.</p>\n<p>Elon Musk, chief executive of Tesla Inc, tweeted that he is \"thinking of quitting my jobs & becoming an influencer full-time.\" The electric car maker's stock advanced 1.3%.</p>\n<p>Southwest Airlines dropped 3.8% after Goldman Sachs downgraded the commercial air carrier's shares to \"sell\" from \"neutral.\"</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.05-to-1 ratio; on Nasdaq, a 1.48-to-1 ratio favored decliners.</p>\n<p>The S&P 500 posted 38 new 52-week highs and <a href=\"https://laohu8.com/S/AONE.U\">one</a> new low; the Nasdaq Composite recorded 34 new highs and 155 new lows.</p>\n<p>Volume on U.S. exchanges was 9.60 billion shares, compared with the 11.42 billion average over the last 20 trading days.</p>\n<p>(Reporting by Stephen Culp in New York Additional reporting by Devik Jain, Shreyashi Sanyal and Bansari Mayur Kamdar in Bengaluru Editing by Matthew Lewis)</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US STOCKS-Wall Street gains, S&P hits record closing high as CPI meets expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS STOCKS-Wall Street gains, S&P hits record closing high as CPI meets expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-11 05:27 GMT+8 <a href=https://finance.yahoo.com/news/us-stocks-wall-street-gains-212756605.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.)\n* Annual CPI growth hits highest level in more than 39 years\n* S&P registers biggest ...</p>\n\n<a href=\"https://finance.yahoo.com/news/us-stocks-wall-street-gains-212756605.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4539":"次新股","COMP":"Compass, Inc.","CPI":"IQ Real Return ETF",".IXIC":"NASDAQ Composite","BK4079":"房地产服务",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://finance.yahoo.com/news/us-stocks-wall-street-gains-212756605.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2190767366","content_text":"(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.)\n* Annual CPI growth hits highest level in more than 39 years\n* S&P registers biggest weekly percentage gain since Feb\n* Oracle leaps on upbeat quarterly results, outlook\n* Broadcom gains on buyback plan announcement\n* Indexes up: Dow 0.60%, S&P 0.95%, Nasdaq 0.73% (Updates with closing prices, adds market details)\nNEW YORK, Dec 10 (Reuters) - Wall Street advanced on Friday and the S&P 500 notched an all-time closing high, as market participants digested an inflation reading that was in line with consensus, but also marked the largest annual increase in consumer prices in nearly four decades.\nAll three major U.S. stock indexes advanced, with tech shares doing the heavy lifting.\nThe indexes all ended the session higher than last Friday's close, and the benchmark S&P 500 posted its biggest weekly percentage advance since the week ended Feb. 5, as waning jitters over the Omicron coronavirus variant helped fuel a broad rally early in the week.\nA report from the Labor Department showed consumer prices surged last month to a 6.8% annual growth rate, the highest reading in more than 39 years.\n\"It would appear that today’s reaction would indicate the markets were discounting the (CPI) reading,\" said Chuck Carlson, chief executive officer at Horizon Investment Services in Hammond, Indiana. \"The markets are always looking forward and perhaps today's reading is indicative of a peak versus a sustained level.\"\nPersistent inflation due to ongoing supply-chain challenges suggests the U.S. Federal Reserve could very well start tightening its accommodative monetary policy sooner than many might have hoped.\n\"Clearly, it’s being driven primarily by supply-chain issues,\" Said Tim Ghriskey, senior portfolio strategist at Inverness Counsel in New York. \"But it appears these issues could be easing, and over time we should see them moderate. And that should take the foot off the inflation accelerator.\"\nA Reuters poll of economists sees the central bank hiking key interest rates from near zero to 0.25-0.50% in the third quarter of next year, followed by another in the fourth quarter.\nThe Fed is expected to convene next week for its two-day monetary policy meeting, which market participants will be scrutinizing for any clues regarding those rate increases along with the pace at which it will taper its bond purchases.\n\"The Fed is has telegraphed on tightening sooner rather than later,\" Carlson added. \"The markets are more comfortable with Fed tightening if it reduces inflation expectations.\"\nThe graphic below shows core CPI along with other major U.S. indicators, all of which continue to soar well above the Fed's average annual 2% inflation target:\nThe Dow Jones Industrial Average rose 216.3 points, or 0.6%, to 35,970.99, the S&P 500 gained 44.57 points, or 0.95%, to 4,712.02 and the Nasdaq Composite added 113.23 points, or 0.73%, to 15,630.60.\nAll 11 major sectors in the S&P 500 ended the session green, with technology and consumer staples enjoying the largest percentage jumps.\nShares of software firm Oracle Corp jumped 15.6% after it forecast an upbeat third-quarter outlook.\nBroadcom Inc gained 8.3% following the chipmaker's announcement of a $10 billion share buyback plan.\nElon Musk, chief executive of Tesla Inc, tweeted that he is \"thinking of quitting my jobs & becoming an influencer full-time.\" The electric car maker's stock advanced 1.3%.\nSouthwest Airlines dropped 3.8% after Goldman Sachs downgraded the commercial air carrier's shares to \"sell\" from \"neutral.\"\nDeclining issues outnumbered advancing ones on the NYSE by a 1.05-to-1 ratio; on Nasdaq, a 1.48-to-1 ratio favored decliners.\nThe S&P 500 posted 38 new 52-week highs and one new low; the Nasdaq Composite recorded 34 new highs and 155 new lows.\nVolume on U.S. exchanges was 9.60 billion shares, compared with the 11.42 billion average over the last 20 trading days.\n(Reporting by Stephen Culp in New York Additional reporting by Devik Jain, Shreyashi Sanyal and Bansari Mayur Kamdar in Bengaluru Editing by Matthew Lewis)","news_type":1},"isVote":1,"tweetType":1,"viewCount":547,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":864770396,"gmtCreate":1633155406450,"gmtModify":1633155407869,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/864770396","repostId":"1134305481","repostType":4,"repost":{"id":"1134305481","pubTimestamp":1633152909,"share":"https://www.laohu8.com/m/news/1134305481?lang=&edition=full","pubTime":"2021-10-02 13:35","market":"hk","language":"en","title":"3 Stocks That Can Double Again in the Fourth Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=1134305481","media":"The motley fool","summary":"Key Points\n\nCrocs has jacked up its guidance every quarter this year. It reports again later this mo","content":"<p>Key Points</p>\n<ul>\n <li>Crocs has jacked up its guidance every quarter this year. It reports again later this month.</li>\n <li>AMC would have to double from here to revisit its June highs. Check the upcoming theatrical release slate to know why movie theaters are about to get a whole lot better.</li>\n <li>Upstart is revolutionizing the way creditworthiness is determined in consumer loans, and it's laughing all the way to the bank.</li>\n</ul>\n<p></p>\n<p>It's been a volatile year for stocks, but naturally some investments have fared better than others. Over 300 stocks have more than doubled in 2021. Many of those winning investments will be lucky if they can hold those gains through the final three months of the year, but what about the names that have the potential to double again?</p>\n<p><b>Crocs</b> (NASDAQ:CROX),<b>AMC Entertainment</b>(NYSE:AMC), and<b>Upstart</b> (NASDAQ:UPST)have more than doubled in value through the first nine months of 2021. Let's see why they have what it takes to possibly repeat the feat in the fourth quarter.</p>\n<p>1. Crocs</p>\n<p>Remember those bright rubbery shoes with holes in them? They're back in a big way. Crocs sales are booming since the pandemic began, and the stock is following suit with a 129% increase through the first nine months of 2021.</p>\n<p>The comfortable resin shoes were already making a comeback before the COVID-19 crisis with double-digit revenue growth in 2019 before repeating the feat in 2020. Momentum is what's really taking Crocs to a higher level in 2021.</p>\n<p>The year began with the footwear maker projecting 20%-to-25% top-line growth for the entire year back in February. Guidance was bumped higher -- to between 40% and 50% growth -- the following quarter. It happened again this summer, with Crocs now targeting a 60%-to-65% surge in revenue for all of 2021. What do you think will happen if those targets get pushed even higher when it reports third-quarter results later this month?</p>\n<p>Despite a stock that has popped nearly sixfold since the start of 2019, Crocs is reasonably priced given its accelerating growth. It's trading at 21 times this year's earnings and just 17 times next year's target. There's clearly room to increase those multiples, and Wall Street's finally as comfortable with Crocs as an investment as its customers are in its shoes.</p>\n<p>2. AMC Entertainment</p>\n<p>You may be surprised to find the country's leading multiplex operator on this list, but plot twists are what make movies so good. It's certainly true that AMC Entertainment has appreciated -- in terms of both stock price and a fivefold explosion in shares outstanding -- to the point where its valuation is out of whack relative to its peers'. If you want a pure investing play on the movie theater industry's recovery, you will find more attractively priced stocks toscratchthatitch.</p>\n<p>However, as ameme stockand cultural phenomenon it's hard to argue against what AMC has done to translate its popularity among retail investors into a legitimate market share grab in the recovery process. No company has seen its market cap inflate as much as AMC has this year, but this is also a stock that enters the fourth quarter with a stock price that is a little more than half of what it was when it peaked in June. In short, it would have to double from here to revisit its all-time high -- but isn't that always possible with the poster child for 2021 momentum stocks?</p>\n<p>Fundamentally speaking, the catalysts are also there.<i>Shang-Chi and the Legend of the Ten Rings</i>shattered box office records over Labor Day weekend, but the initial excitement fizzled out when subsequent weekends were abysmal. However, it's all about the pipeline. Studios pushed out September releases into October and beyond when the delta variant resulted in a spike in COVID-19 cases. We're now seeing the highly anticipated films start to come back, starting with the new James Bond movie next weekend. The fourth quarter should be a lot stronger for the industry than the naysayers think, and if AMC stock gets back to where it was in early June -- fundamentally earned this time -- it will have to double from here.</p>\n<p>3. Upstart</p>\n<p>I love when industries ripe for disruption get upended, and that's what Upstart is doing with the lending industry. Upstart usesartificial intelligenceand machine learning to make better calls on assessing risk profiles and creditworthiness for folks who don't typically get approved for consumer loans.</p>\n<p>Growth is bonkers. Revenue seemed to be decelerating sharply, with slowing growth spurts of 89%, 52%, and 27% in the last three years respectively. Now that consumers are becoming aware of Upstart as a better alternative to payday loans and other predatory lending products, business is skyrocketing. Revenue rose 90% in the first quarter, only to surge 1,018% in its latest report. And no, that's not a typo.</p>\n<p>With Upstart now expanding into the auto loans market, the potential for its better alternative to stodgy credit scores is just getting started. The stock has been a seven-bagger through the first three quarters of 2021, but the runway is long for this disruptive jet.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Can Double Again in the Fourth Quarter</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Can Double Again in the Fourth Quarter\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-02 13:35 GMT+8 <a href=https://www.fool.com/investing/2021/10/01/3-stocks-that-can-double-again-in-the-fourth-quart/><strong>The motley fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nCrocs has jacked up its guidance every quarter this year. It reports again later this month.\nAMC would have to double from here to revisit its June highs. Check the upcoming theatrical ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/01/3-stocks-that-can-double-again-in-the-fourth-quart/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CROX":"卡骆驰","UPST":"Upstart Holdings, Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/10/01/3-stocks-that-can-double-again-in-the-fourth-quart/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134305481","content_text":"Key Points\n\nCrocs has jacked up its guidance every quarter this year. It reports again later this month.\nAMC would have to double from here to revisit its June highs. Check the upcoming theatrical release slate to know why movie theaters are about to get a whole lot better.\nUpstart is revolutionizing the way creditworthiness is determined in consumer loans, and it's laughing all the way to the bank.\n\n\nIt's been a volatile year for stocks, but naturally some investments have fared better than others. Over 300 stocks have more than doubled in 2021. Many of those winning investments will be lucky if they can hold those gains through the final three months of the year, but what about the names that have the potential to double again?\nCrocs (NASDAQ:CROX),AMC Entertainment(NYSE:AMC), andUpstart (NASDAQ:UPST)have more than doubled in value through the first nine months of 2021. Let's see why they have what it takes to possibly repeat the feat in the fourth quarter.\n1. Crocs\nRemember those bright rubbery shoes with holes in them? They're back in a big way. Crocs sales are booming since the pandemic began, and the stock is following suit with a 129% increase through the first nine months of 2021.\nThe comfortable resin shoes were already making a comeback before the COVID-19 crisis with double-digit revenue growth in 2019 before repeating the feat in 2020. Momentum is what's really taking Crocs to a higher level in 2021.\nThe year began with the footwear maker projecting 20%-to-25% top-line growth for the entire year back in February. Guidance was bumped higher -- to between 40% and 50% growth -- the following quarter. It happened again this summer, with Crocs now targeting a 60%-to-65% surge in revenue for all of 2021. What do you think will happen if those targets get pushed even higher when it reports third-quarter results later this month?\nDespite a stock that has popped nearly sixfold since the start of 2019, Crocs is reasonably priced given its accelerating growth. It's trading at 21 times this year's earnings and just 17 times next year's target. There's clearly room to increase those multiples, and Wall Street's finally as comfortable with Crocs as an investment as its customers are in its shoes.\n2. AMC Entertainment\nYou may be surprised to find the country's leading multiplex operator on this list, but plot twists are what make movies so good. It's certainly true that AMC Entertainment has appreciated -- in terms of both stock price and a fivefold explosion in shares outstanding -- to the point where its valuation is out of whack relative to its peers'. If you want a pure investing play on the movie theater industry's recovery, you will find more attractively priced stocks toscratchthatitch.\nHowever, as ameme stockand cultural phenomenon it's hard to argue against what AMC has done to translate its popularity among retail investors into a legitimate market share grab in the recovery process. No company has seen its market cap inflate as much as AMC has this year, but this is also a stock that enters the fourth quarter with a stock price that is a little more than half of what it was when it peaked in June. In short, it would have to double from here to revisit its all-time high -- but isn't that always possible with the poster child for 2021 momentum stocks?\nFundamentally speaking, the catalysts are also there.Shang-Chi and the Legend of the Ten Ringsshattered box office records over Labor Day weekend, but the initial excitement fizzled out when subsequent weekends were abysmal. However, it's all about the pipeline. Studios pushed out September releases into October and beyond when the delta variant resulted in a spike in COVID-19 cases. We're now seeing the highly anticipated films start to come back, starting with the new James Bond movie next weekend. The fourth quarter should be a lot stronger for the industry than the naysayers think, and if AMC stock gets back to where it was in early June -- fundamentally earned this time -- it will have to double from here.\n3. Upstart\nI love when industries ripe for disruption get upended, and that's what Upstart is doing with the lending industry. Upstart usesartificial intelligenceand machine learning to make better calls on assessing risk profiles and creditworthiness for folks who don't typically get approved for consumer loans.\nGrowth is bonkers. Revenue seemed to be decelerating sharply, with slowing growth spurts of 89%, 52%, and 27% in the last three years respectively. Now that consumers are becoming aware of Upstart as a better alternative to payday loans and other predatory lending products, business is skyrocketing. Revenue rose 90% in the first quarter, only to surge 1,018% in its latest report. And no, that's not a typo.\nWith Upstart now expanding into the auto loans market, the potential for its better alternative to stodgy credit scores is just getting started. The stock has been a seven-bagger through the first three quarters of 2021, but the runway is long for this disruptive jet.","news_type":1},"isVote":1,"tweetType":1,"viewCount":17,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602915546,"gmtCreate":1638956253196,"gmtModify":1638956689133,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Woo","listText":"Woo","text":"Woo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602915546","repostId":"1136716851","repostType":4,"repost":{"id":"1136716851","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638955203,"share":"https://www.laohu8.com/m/news/1136716851?lang=&edition=full","pubTime":"2021-12-08 17:20","market":"us","language":"en","title":"Some Vaccine stocks corrected in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1136716851","media":"Tiger Newspress","summary":"Some Vaccine stocks corrected in premarket trading.Novavax,BioNTech SE,Moderna and Pfizer fell betwe","content":"<p>Some Vaccine stocks corrected in premarket trading.Novavax,BioNTech SE,Moderna and Pfizer fell between 3% and 7%.</p>\n<p><img src=\"https://static.tigerbbs.com/b5fc2db6a961be0363c3be880585ad0f\" tg-width=\"404\" tg-height=\"241\" referrerpolicy=\"no-referrer\"></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some Vaccine stocks corrected in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome Vaccine stocks corrected in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-08 17:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Some Vaccine stocks corrected in premarket trading.Novavax,BioNTech SE,Moderna and Pfizer fell between 3% and 7%.</p>\n<p><img src=\"https://static.tigerbbs.com/b5fc2db6a961be0363c3be880585ad0f\" tg-width=\"404\" tg-height=\"241\" referrerpolicy=\"no-referrer\"></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136716851","content_text":"Some Vaccine stocks corrected in premarket trading.Novavax,BioNTech SE,Moderna and Pfizer fell between 3% and 7%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":602,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606504712,"gmtCreate":1638890080088,"gmtModify":1638890089373,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"999","listText":"999","text":"999","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606504712","repostId":"1107798974","repostType":4,"repost":{"id":"1107798974","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638889130,"share":"https://www.laohu8.com/m/news/1107798974?lang=&edition=full","pubTime":"2021-12-07 22:58","market":"us","language":"en","title":"777 Partners Orders 30 Additional 737 MAX Airplanes","url":"https://stock-news.laohu8.com/highlight/detail?id=1107798974","media":"Tiger Newspress","summary":"Boeing's stock extends bounce after receiving additional order for 30 737 MAX jets from 777 Partners","content":"<p>Boeing's stock extends bounce after receiving additional order for 30 737 MAX jets from 777 Partners.</p>\n<p><img src=\"https://static.tigerbbs.com/c0a9ddf262204e94020bb4a124cc1b01\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>Boeing and 777 Partners today announced the Miami-based investment firm will nearly double its 737 MAX order book with the purchase of 30 additional jets. The new order expands 777 Partners' commercial aircraft portfolio to a total of 68 737 MAXs, in its fourth order this year for the fuel-efficient, single-aisle jets. Valued at $3.7 billion at list prices, the order will enable 777 Partners to expand 737 MAX operations across the fleet of its affiliated global low-cost carriers.</p>\n<p>\"We're delighted to be able to announce the almost doubling in size of our order with Boeing,\" said Josh Wander, managing partner of 777 Partners. \"We have long been confident in the economics of the 737 MAX family but we are especially excited about the 737-8-200 variant which represents the bulk of our additional orders. We're confident that this aircraft will be the hallmark ULCC/LCC asset, particularly in the sub-200 seat market. As travel demand returns, 777 has accelerated our quest for efficiencies in both operating cost and carbon footprint at our operating carriers. . In these areas the 737-8 is compelling and the 737-8-200 is simply unrivalled.\"</p>\n<p>The 737 MAX family reduces fuel use and carbon emissions by at least 14% compared to the airplanes it replaces, reducing operating costs as well as the environmental footprint for 777 Partners' affiliated airlines. Every 737 MAX features a passenger-pleasing Boeing Sky Interior, highlighted by modern sculpted sidewalls and window reveals, LED lighting that enhances the sense of spaciousness and larger pivoting overhead storage bins.</p>\n<p>\"We greatly appreciate 777 Partners for their trust in our products, including repeat orders for the 737 MAX and expanding their fleet to include the high-capacity 737-8-200 model,\" said Ihssane Mounir, Boeing senior vice president of Commercial Sales and Marketing. \"777 Partners is enabling growth for its affiliated low-cost carriers by leveraging the 737 family's flexibility, reliability and efficiency to serve passengers for years to come.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>777 Partners Orders 30 Additional 737 MAX Airplanes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n777 Partners Orders 30 Additional 737 MAX Airplanes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-07 22:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Boeing's stock extends bounce after receiving additional order for 30 737 MAX jets from 777 Partners.</p>\n<p><img src=\"https://static.tigerbbs.com/c0a9ddf262204e94020bb4a124cc1b01\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>Boeing and 777 Partners today announced the Miami-based investment firm will nearly double its 737 MAX order book with the purchase of 30 additional jets. The new order expands 777 Partners' commercial aircraft portfolio to a total of 68 737 MAXs, in its fourth order this year for the fuel-efficient, single-aisle jets. Valued at $3.7 billion at list prices, the order will enable 777 Partners to expand 737 MAX operations across the fleet of its affiliated global low-cost carriers.</p>\n<p>\"We're delighted to be able to announce the almost doubling in size of our order with Boeing,\" said Josh Wander, managing partner of 777 Partners. \"We have long been confident in the economics of the 737 MAX family but we are especially excited about the 737-8-200 variant which represents the bulk of our additional orders. We're confident that this aircraft will be the hallmark ULCC/LCC asset, particularly in the sub-200 seat market. As travel demand returns, 777 has accelerated our quest for efficiencies in both operating cost and carbon footprint at our operating carriers. . In these areas the 737-8 is compelling and the 737-8-200 is simply unrivalled.\"</p>\n<p>The 737 MAX family reduces fuel use and carbon emissions by at least 14% compared to the airplanes it replaces, reducing operating costs as well as the environmental footprint for 777 Partners' affiliated airlines. Every 737 MAX features a passenger-pleasing Boeing Sky Interior, highlighted by modern sculpted sidewalls and window reveals, LED lighting that enhances the sense of spaciousness and larger pivoting overhead storage bins.</p>\n<p>\"We greatly appreciate 777 Partners for their trust in our products, including repeat orders for the 737 MAX and expanding their fleet to include the high-capacity 737-8-200 model,\" said Ihssane Mounir, Boeing senior vice president of Commercial Sales and Marketing. \"777 Partners is enabling growth for its affiliated low-cost carriers by leveraging the 737 family's flexibility, reliability and efficiency to serve passengers for years to come.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BA":"波音"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107798974","content_text":"Boeing's stock extends bounce after receiving additional order for 30 737 MAX jets from 777 Partners.\n\nBoeing and 777 Partners today announced the Miami-based investment firm will nearly double its 737 MAX order book with the purchase of 30 additional jets. The new order expands 777 Partners' commercial aircraft portfolio to a total of 68 737 MAXs, in its fourth order this year for the fuel-efficient, single-aisle jets. Valued at $3.7 billion at list prices, the order will enable 777 Partners to expand 737 MAX operations across the fleet of its affiliated global low-cost carriers.\n\"We're delighted to be able to announce the almost doubling in size of our order with Boeing,\" said Josh Wander, managing partner of 777 Partners. \"We have long been confident in the economics of the 737 MAX family but we are especially excited about the 737-8-200 variant which represents the bulk of our additional orders. We're confident that this aircraft will be the hallmark ULCC/LCC asset, particularly in the sub-200 seat market. As travel demand returns, 777 has accelerated our quest for efficiencies in both operating cost and carbon footprint at our operating carriers. . In these areas the 737-8 is compelling and the 737-8-200 is simply unrivalled.\"\nThe 737 MAX family reduces fuel use and carbon emissions by at least 14% compared to the airplanes it replaces, reducing operating costs as well as the environmental footprint for 777 Partners' affiliated airlines. Every 737 MAX features a passenger-pleasing Boeing Sky Interior, highlighted by modern sculpted sidewalls and window reveals, LED lighting that enhances the sense of spaciousness and larger pivoting overhead storage bins.\n\"We greatly appreciate 777 Partners for their trust in our products, including repeat orders for the 737 MAX and expanding their fleet to include the high-capacity 737-8-200 model,\" said Ihssane Mounir, Boeing senior vice president of Commercial Sales and Marketing. \"777 Partners is enabling growth for its affiliated low-cost carriers by leveraging the 737 family's flexibility, reliability and efficiency to serve passengers for years to come.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":567,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609092790,"gmtCreate":1638205960970,"gmtModify":1638205962476,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TWTR\">$Twitter(TWTR)$</a>Buy buy buy ","listText":"<a href=\"https://laohu8.com/S/TWTR\">$Twitter(TWTR)$</a>Buy buy buy ","text":"$Twitter(TWTR)$Buy buy buy","images":[{"img":"https://static.tigerbbs.com/0ff7bb6edd7b6530b6bc91e1b046d6a9","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609092790","isVote":1,"tweetType":1,"viewCount":195,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":600333888,"gmtCreate":1638064959879,"gmtModify":1638064960263,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok ","listText":"Ok ","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600333888","repostId":"2186340224","repostType":4,"repost":{"id":"2186340224","pubTimestamp":1638059445,"share":"https://www.laohu8.com/m/news/2186340224?lang=&edition=full","pubTime":"2021-11-28 08:30","market":"us","language":"en","title":"Got $5,000? These 2 Stocks Could Be Bargain Buys in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2186340224","media":"Motley Fool","summary":"Both of these businesses could be in much better shape a year from now.","content":"<p>Investing in stocks that are falling can be tough to do; nobody wants to look at their portfolio and see red. But if you're investing for the long haul, you know that short-term trends could subside, and this year's sell-off stock could be next year's top performer.</p>\n<p>That's exactly what I think of with <a href=\"https://laohu8.com/S/AZN\"><b>AstraZeneca </b></a> and <a href=\"https://laohu8.com/S/BYND\"><b>Beyond Meat </b></a>. Both of these stocks have been falling recently, but heading into next year, things could look a lot better. If you can afford to invest $5,000 into these stocks, here's why you should consider doing so.</p>\n<h4><b>1. AstraZeneca</b></h4>\n<p>Shares of COVID-19 vaccine-maker AstraZeneca are down 5% over the past three months, while the <b>S&P 500</b> has soared by more than 5%. The company released its third-quarter results on Nov. 12, which disappointed investors as it fell short of earnings expectations. The stock sank more than 6% on the day.</p>\n<p>But next year, things could look much different. Up until now, AstraZeneca hasn't been trying to make a profit from its COVID-19 vaccine. But now that the pandemic is turning into more of an endemic, the company is going to focus on turning a profit on the vaccine on any new orders.</p>\n<p>That means an increase in price. The company has been selling its vaccine for just a few dollars per dose, well below what other COVID-19 vaccine makers are charging countries.</p>\n<p>For the period ending Sept. 30, the company's COVID-19 vaccine generated over $1 billion in revenue. Meanwhile, rival vaccine-maker <b>Moderna</b> reported $4.8 billion in product sales for the same period, and <b>Pfizer</b>'s COVID-19 vaccine generated $13 billion in revenue, also during the same interval.</p>\n<p>While it's unclear just how much higher AstraZeneca's COVID-19-related revenue may climb on an increase in the vaccine's price, its top line is likely to get a boost next year nonetheless. Plus, it completed the acquisition of healthcare-company Alexion Pharmaceuticals in July, which has already started contributing to AstraZeneca's financials this past quarter to the tune of $1.3 billion in new revenue. Alexion's focus on rare diseases expands AstraZeneca's product mix and can set it up for some great gains over the long term.</p>\n<p>Although AstraZeneca incurred a net loss of $1.7 billion this past quarter, that's largely due to the acquisition of Alexion, as its operations are typically profitable. (In each of the previous four quarters, AstraZeneca has reported a profit margin of at least 6%.)</p>\n<p>As it integrates Alexion into its business and eliminates inefficiencies and redundancies, the company's financials will improve. That, combined with the additional revenue from the new business plus an increase in COVID-19 sales, could set the stock up for a terrific performance in 2022.</p>\n<h4><b>2. Beyond Meat</b></h4>\n<p>Beyond Meat's stock has been falling fast as it's down 36% in just three months. What was looking like it might be a promising year for the company amid reopenings has stalled due to the delta variant causing a spike in COVID-19 cases.</p>\n<p>The company had a bad earnings report and the stock has become a better buy in November. Although sales of $106.4 million for the period ending Oct. 2 rose 13% year over year, the company disappointed investors with a net loss of $54.8 million that was more than double the $19.3 million loss it reported in the same period in 2020. Beyond Meat doesn't project a picture of getting much better in the final quarter of the year, as it expects net revenue to fall within a range of just $85 million to $110 million.</p>\n<p>There's no shortage of bearishness surrounding Beyond Meat right now. But heading into next year, a lot can change. What's important is that the company has some great growth opportunities in place.</p>\n<p>Beyond's sales were up 13% this past quarter, but that was driven primarily by growth in the international markets, where revenue more than doubled to $38.9 million. In the U.S. market, sales of $67.5 million declined by 14%.</p>\n<p>However, if supply-chain issues resolve next year and COVID-19 case numbers come down as people receive booster shots, there's reason to believe that the U.S. numbers could strengthen with a return to normalcy in the economy. And fast-food restaurant <b>McDonald's</b> recently launched its McPlant burger (which features a Beyond Meat patty) in multiple U.S. cities. If successful, that could also lead to some improved financials for Beyond in 2022.</p>\n<p>Although the growth stock is beaten up today, a year from now, today's price could look like a bargain.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $5,000? These 2 Stocks Could Be Bargain Buys in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $5,000? These 2 Stocks Could Be Bargain Buys in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-28 08:30 GMT+8 <a href=https://www.fool.com/investing/2021/11/27/these-2-stocks-could-be-bargain-buys-in-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing in stocks that are falling can be tough to do; nobody wants to look at their portfolio and see red. But if you're investing for the long haul, you know that short-term trends could subside, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/27/these-2-stocks-could-be-bargain-buys-in-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","AZN":"阿斯利康"},"source_url":"https://www.fool.com/investing/2021/11/27/these-2-stocks-could-be-bargain-buys-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2186340224","content_text":"Investing in stocks that are falling can be tough to do; nobody wants to look at their portfolio and see red. But if you're investing for the long haul, you know that short-term trends could subside, and this year's sell-off stock could be next year's top performer.\nThat's exactly what I think of with AstraZeneca and Beyond Meat . Both of these stocks have been falling recently, but heading into next year, things could look a lot better. If you can afford to invest $5,000 into these stocks, here's why you should consider doing so.\n1. AstraZeneca\nShares of COVID-19 vaccine-maker AstraZeneca are down 5% over the past three months, while the S&P 500 has soared by more than 5%. The company released its third-quarter results on Nov. 12, which disappointed investors as it fell short of earnings expectations. The stock sank more than 6% on the day.\nBut next year, things could look much different. Up until now, AstraZeneca hasn't been trying to make a profit from its COVID-19 vaccine. But now that the pandemic is turning into more of an endemic, the company is going to focus on turning a profit on the vaccine on any new orders.\nThat means an increase in price. The company has been selling its vaccine for just a few dollars per dose, well below what other COVID-19 vaccine makers are charging countries.\nFor the period ending Sept. 30, the company's COVID-19 vaccine generated over $1 billion in revenue. Meanwhile, rival vaccine-maker Moderna reported $4.8 billion in product sales for the same period, and Pfizer's COVID-19 vaccine generated $13 billion in revenue, also during the same interval.\nWhile it's unclear just how much higher AstraZeneca's COVID-19-related revenue may climb on an increase in the vaccine's price, its top line is likely to get a boost next year nonetheless. Plus, it completed the acquisition of healthcare-company Alexion Pharmaceuticals in July, which has already started contributing to AstraZeneca's financials this past quarter to the tune of $1.3 billion in new revenue. Alexion's focus on rare diseases expands AstraZeneca's product mix and can set it up for some great gains over the long term.\nAlthough AstraZeneca incurred a net loss of $1.7 billion this past quarter, that's largely due to the acquisition of Alexion, as its operations are typically profitable. (In each of the previous four quarters, AstraZeneca has reported a profit margin of at least 6%.)\nAs it integrates Alexion into its business and eliminates inefficiencies and redundancies, the company's financials will improve. That, combined with the additional revenue from the new business plus an increase in COVID-19 sales, could set the stock up for a terrific performance in 2022.\n2. Beyond Meat\nBeyond Meat's stock has been falling fast as it's down 36% in just three months. What was looking like it might be a promising year for the company amid reopenings has stalled due to the delta variant causing a spike in COVID-19 cases.\nThe company had a bad earnings report and the stock has become a better buy in November. Although sales of $106.4 million for the period ending Oct. 2 rose 13% year over year, the company disappointed investors with a net loss of $54.8 million that was more than double the $19.3 million loss it reported in the same period in 2020. Beyond Meat doesn't project a picture of getting much better in the final quarter of the year, as it expects net revenue to fall within a range of just $85 million to $110 million.\nThere's no shortage of bearishness surrounding Beyond Meat right now. But heading into next year, a lot can change. What's important is that the company has some great growth opportunities in place.\nBeyond's sales were up 13% this past quarter, but that was driven primarily by growth in the international markets, where revenue more than doubled to $38.9 million. In the U.S. market, sales of $67.5 million declined by 14%.\nHowever, if supply-chain issues resolve next year and COVID-19 case numbers come down as people receive booster shots, there's reason to believe that the U.S. numbers could strengthen with a return to normalcy in the economy. And fast-food restaurant McDonald's recently launched its McPlant burger (which features a Beyond Meat patty) in multiple U.S. cities. If successful, that could also lead to some improved financials for Beyond in 2022.\nAlthough the growth stock is beaten up today, a year from now, today's price could look like a bargain.","news_type":1},"isVote":1,"tweetType":1,"viewCount":32,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849737095,"gmtCreate":1635776905174,"gmtModify":1635776905581,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Great deals ","listText":"Great deals ","text":"Great deals","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849737095","repostId":"1183354594","repostType":4,"repost":{"id":"1183354594","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635775510,"share":"https://www.laohu8.com/m/news/1183354594?lang=&edition=full","pubTime":"2021-11-01 22:05","market":"us","language":"en","title":"Chinese e-commerce stocks rose sharply on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1183354594","media":"Tiger Newspress","summary":"Chinese e-commerce stocks rose sharply on Monday.Alibaba,JD.com,Pinduoduo,Vipshop and Baozun all surged more than 3%.","content":"<p>Chinese e-commerce stocks rose sharply on Monday.Alibaba,JD.com,Pinduoduo,Vipshop and Baozun all surged more than 3%.</p>\n<p><img src=\"https://static.tigerbbs.com/f34ff03fe341c79c9f7a18ea4662bfcf\" tg-width=\"400\" tg-height=\"302\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese e-commerce stocks rose sharply on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese e-commerce stocks rose sharply on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-01 22:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Chinese e-commerce stocks rose sharply on Monday.Alibaba,JD.com,Pinduoduo,Vipshop and Baozun all surged more than 3%.</p>\n<p><img src=\"https://static.tigerbbs.com/f34ff03fe341c79c9f7a18ea4662bfcf\" tg-width=\"400\" tg-height=\"302\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BABA":"阿里巴巴"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183354594","content_text":"Chinese e-commerce stocks rose sharply on Monday.Alibaba,JD.com,Pinduoduo,Vipshop and Baozun all surged more than 3%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":31,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":858075148,"gmtCreate":1634957783952,"gmtModify":1634957785254,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Go go","listText":"Go go","text":"Go go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/858075148","repostId":"2177419115","repostType":2,"repost":{"id":"2177419115","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1634919955,"share":"https://www.laohu8.com/m/news/2177419115?lang=&edition=full","pubTime":"2021-10-23 00:25","market":"us","language":"en","title":"S&P Says Tesla Inc. Upgraded To 'BB+' On Solid Demand Prospects And Robust Financial Metrics; Outlook Positive","url":"https://stock-news.laohu8.com/highlight/detail?id=2177419115","media":"Reuters","summary":"S&P:S&P Says Tesla Inc. Upgraded To 'Bb+' On Solid Demand Prospects And Robust Financial Metrics; Outlook Positive.S&P, On Tesla, Says Positive Outlook Reflects Our View That Tesla'S Free Operating Cash Flow Generation Will Remain Positive More Consistently.S&P Says Despite Semiconductor Shortages, Other Supply-Related Bottlenecks, Tesla Appears To Have Minimized Production Disruption Versus Most Automakers.S&P Says View On Tesla Also Reflects Outperformance Of Electric Vehicles So Far This Yea","content":"<html><body><p>S&P:S&P Says Tesla Inc. Upgraded To 'Bb+' On Solid Demand Prospects And Robust Financial Metrics; Outlook Positive.S&P, On Tesla, Says Positive Outlook Reflects Our View That Tesla'S Free Operating Cash Flow Generation Will Remain Positive More Consistently.S&P Says Despite Semiconductor Shortages, Other Supply-Related Bottlenecks, Tesla Appears To Have Minimized Production Disruption Versus Most Automakers.S&P Says View On Tesla Also Reflects Outperformance Of Electric Vehicles (Evs) So Far This Year Globally.S&P Says Key Risks Going Forward Include Access To Supply As Tesla Looks To Raise Cell Capacity And Complete Its Production Ramp-Up To Meet Demand.S&P Says Despite Near-Term Supply Bottlenecks For The Industry, We Expect Tesla Deliveries And Earnings To Remain Strong Over The Next Few Quarters.Further Company Coverage: Tsla.O. ((Reuters.Briefs@Thomsonreuters.Com;)).</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P Says Tesla Inc. Upgraded To 'BB+' On Solid Demand Prospects And Robust Financial Metrics; Outlook Positive</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P Says Tesla Inc. Upgraded To 'BB+' On Solid Demand Prospects And Robust Financial Metrics; Outlook Positive\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-10-23 00:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>S&P:S&P Says Tesla Inc. Upgraded To 'Bb+' On Solid Demand Prospects And Robust Financial Metrics; Outlook Positive.S&P, On Tesla, Says Positive Outlook Reflects Our View That Tesla'S Free Operating Cash Flow Generation Will Remain Positive More Consistently.S&P Says Despite Semiconductor Shortages, Other Supply-Related Bottlenecks, Tesla Appears To Have Minimized Production Disruption Versus Most Automakers.S&P Says View On Tesla Also Reflects Outperformance Of Electric Vehicles (Evs) So Far This Year Globally.S&P Says Key Risks Going Forward Include Access To Supply As Tesla Looks To Raise Cell Capacity And Complete Its Production Ramp-Up To Meet Demand.S&P Says Despite Near-Term Supply Bottlenecks For The Industry, We Expect Tesla Deliveries And Earnings To Remain Strong Over The Next Few Quarters.Further Company Coverage: Tsla.O. ((Reuters.Briefs@Thomsonreuters.Com;)).</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TERN":"Terns Pharmaceuticals, Inc.","CRCT":"Cricut, Inc.","FWRG":"First Watch Restaurant Group, Inc.","TSLA":"特斯拉","OLPX":"Olaplex Holdings, Inc.","HCTI":"Healthcare Triangle, Inc."},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2177419115","content_text":"S&P:S&P Says Tesla Inc. Upgraded To 'Bb+' On Solid Demand Prospects And Robust Financial Metrics; Outlook Positive.S&P, On Tesla, Says Positive Outlook Reflects Our View That Tesla'S Free Operating Cash Flow Generation Will Remain Positive More Consistently.S&P Says Despite Semiconductor Shortages, Other Supply-Related Bottlenecks, Tesla Appears To Have Minimized Production Disruption Versus Most Automakers.S&P Says View On Tesla Also Reflects Outperformance Of Electric Vehicles (Evs) So Far This Year Globally.S&P Says Key Risks Going Forward Include Access To Supply As Tesla Looks To Raise Cell Capacity And Complete Its Production Ramp-Up To Meet Demand.S&P Says Despite Near-Term Supply Bottlenecks For The Industry, We Expect Tesla Deliveries And Earnings To Remain Strong Over The Next Few Quarters.Further Company Coverage: Tsla.O. ((Reuters.Briefs@Thomsonreuters.Com;)).","news_type":1},"isVote":1,"tweetType":1,"viewCount":15,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":820216745,"gmtCreate":1633395053618,"gmtModify":1633395055061,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"✅ ","listText":"✅ ","text":"✅","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820216745","repostId":"2173617992","repostType":4,"repost":{"id":"2173617992","pubTimestamp":1633390072,"share":"https://www.laohu8.com/m/news/2173617992?lang=&edition=full","pubTime":"2021-10-05 07:27","market":"sg","language":"en","title":"Oil jumps above US$81 with Opec+ sticking to output increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2173617992","media":"The Straits Times","summary":"BENGALURU (REUTERS) - Oil jumped to a three-year peak on Monday (Oct 4) after Opec+ confirmed it wou","content":"<div>\n<p>BENGALURU (REUTERS) - Oil jumped to a three-year peak on Monday (Oct 4) after Opec+ confirmed it would stick to its current output policy as demand for petroleum products rebounds, despite pressure ...</p>\n\n<a href=\"http://www.straitstimes.com/business/companies-markets/oil-jumps-above-us81-with-opec-sticking-to-output-increase\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oil jumps above US$81 with Opec+ sticking to output increase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOil jumps above US$81 with Opec+ sticking to output increase\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-05 07:27 GMT+8 <a href=http://www.straitstimes.com/business/companies-markets/oil-jumps-above-us81-with-opec-sticking-to-output-increase><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BENGALURU (REUTERS) - Oil jumped to a three-year peak on Monday (Oct 4) after Opec+ confirmed it would stick to its current output policy as demand for petroleum products rebounds, despite pressure ...</p>\n\n<a href=\"http://www.straitstimes.com/business/companies-markets/oil-jumps-above-us81-with-opec-sticking-to-output-increase\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"http://www.straitstimes.com/business/companies-markets/oil-jumps-above-us81-with-opec-sticking-to-output-increase","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2173617992","content_text":"BENGALURU (REUTERS) - Oil jumped to a three-year peak on Monday (Oct 4) after Opec+ confirmed it would stick to its current output policy as demand for petroleum products rebounds, despite pressure from some countries for a bigger boost to production.\nThe producer club's decision to keep increasing oil output gradually sent prices sharply higher, adding to inflationary pressures that consuming nations fear will derail an economic recovery from the coronavirus pandemic.\nOpec+ agreed in July to boost output by 400,000 barrels per day (bpd) each month until at least April next year to phase out 5.8 million bpd of existing production cuts.\nBrent crude settled up US$1.98, or 2.5 per cent, to US$81.26 a barrel. It rose 1.5 per cent last week for a fourth consecutive weekly gain, and was back up to highs last seen in 2018.\nUS oil settled up US$1.74, or 2.3 per cent, to US$77.62 a barrel after gaining for the past six weeks, and was at its highest since 2014.\n\"Given the demand picture and the outcome of the Opec meeting, the overall sentiment around crude is bullish,\" said Mr John Kilduff, partner at Again Capital LLC in New York.\nDemand for coal and natural gas has exceeded pre-Covid-19 highs with oil closely trailing, according to energy watchdog, the International Energy Agency. Three-quarters of global energy demand is still met by fossil fuels, with less than a fifth by non-nuclear renewables.\nOpec+, which groups the Organisation of the Petroleum Exporting Countries (Opec) and allies including Russia, has faced pressure from some countries to add back more barrels to the market as demand has recovered faster than expected in some parts of the world.\nFour Opec+ sources told Reuters recently that producers were considering boosting output by more than had already been agreed.\nThe oil price rally has also been fuelled by an even bigger increase in gas prices, which have spiked by 300 per cent, prompting switching to fuel oil and other crude products to generate electricity and for other industrial needs.","news_type":1},"isVote":1,"tweetType":1,"viewCount":52,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699146410,"gmtCreate":1639759405628,"gmtModify":1639760513920,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://static.tigerbbs.com/880c2c0540d75affbc88b2abb02e579b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Tiger","listText":"Tiger","text":"Tiger","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/699146410","repostId":"1113440959","repostType":4,"repost":{"id":"1113440959","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639752802,"share":"https://www.laohu8.com/m/news/1113440959?lang=&edition=full","pubTime":"2021-12-17 22:53","market":"us","language":"en","title":"EV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7% and General Motors sliding 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113440959","media":"Tiger Newspress","summary":"EV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7%, Lordstown","content":"<p>EV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7%, Lordstown Motors sliding 6% and General Motors sliding 5%.<img src=\"https://static.tigerbbs.com/cd629a366b9a963976bc2a56e7c34763\" tg-width=\"282\" tg-height=\"468\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7% and General Motors sliding 5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7% and General Motors sliding 5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-17 22:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>EV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7%, Lordstown Motors sliding 6% and General Motors sliding 5%.<img src=\"https://static.tigerbbs.com/cd629a366b9a963976bc2a56e7c34763\" tg-width=\"282\" tg-height=\"468\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LCID":"Lucid Group Inc","GM":"通用汽车","RIVN":"Rivian Automotive, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113440959","content_text":"EV stocks fell sharply in morning trading ,with Rivian sliding 12%,Lucid Group sliding 7%, Lordstown Motors sliding 6% and General Motors sliding 5%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":652,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}